



US 20200083464A1

(19) **United States**

(12) **Patent Application Publication**  
**Choi et al.**

(10) **Pub. No.: US 2020/0083464 A1**  
(43) **Pub. Date: Mar. 12, 2020**

(54) **ORGANOMETALLIC COMPOUND,  
ORGANIC LIGHT-EMITTING DEVICE  
INCLUDING THE SAME, AND DIAGNOSTIC  
COMPOSITION INCLUDING THE  
ORGANOMETALLIC COMPOUND**

(30) **Foreign Application Priority Data**

Aug. 31, 2018 (KR) ..... 10-2018-0104040  
Aug. 28, 2019 (KR) ..... 10-2019-0105899

**Publication Classification**

(71) Applicant: **Samsung Electronics Co., Ltd.,**  
Suwon-si (KR)

(51) **Int. Cl.**  
*H01L 51/00* (2006.01)  
*C07F 15/00* (2006.01)  
*C09K 11/06* (2006.01)

(72) Inventors: **Hyeonho Choi**, Seoul (KR); **Kyuyoung Hwang**, Anyang-si (KR); **Seungyeon Kwak**, Suwon-si (KR); **Youngmin Nam**, Seoul (KR); **Kum Hee LEE**, Suwon-si (KR); **Aram Jeon**, Suwon-si (KR); **Whail Choi**, Seoul (KR); **Kyungdoc Kim**, Seoul (KR); **Jiho Yoo**, Hwaseong-si (KR); **Younsuk Choi**, Seongnam-si (KR)

(52) **U.S. Cl.**  
CPC ..... *H01L 51/0085* (2013.01); *H01L 51/5088* (2013.01); *C09K 11/06* (2013.01); *C07F 15/0033* (2013.01)

(21) Appl. No.: **16/555,257**


(57) **ABSTRACT**


An organometallic compound represented by Formula 1:

$M(L_1)_{n1}(L_2)_{n2}$  Formula 1

wherein, in Formula 1, M, L<sub>1</sub>, L<sub>2</sub>, n<sub>1</sub> and n<sub>2</sub> are each the same as defined in the detailed description of the specification.

(22) Filed: **Aug. 29, 2019**





**ORGANOMETALLIC COMPOUND,  
ORGANIC LIGHT-EMITTING DEVICE  
INCLUDING THE SAME, AND DIAGNOSTIC  
COMPOSITION INCLUDING THE  
ORGANOMETALLIC COMPOUND**

CROSS-REFERENCE TO RELATED  
APPLICATION

[0001] This application claims priority to Korean Patent Applications Nos. 10-2018-0104040, filed on Aug. 31, 2018, and 10-2019-0105899, filed on Aug. 28, 2019, in the Korean Intellectual Property Office, and all the benefits accruing therefrom under 35 U.S.C. § 119, the content of which is incorporated herein in its entirety by reference.

BACKGROUND

1. Field

[0002] One or more embodiments relate to an organometallic compound, an organic light-emitting device including the organometallic compound, and a diagnostic composition including the organometallic compound.

2. Description of the Related Art

[0003] Organic light-emitting devices (OLEDs) are self-emission devices, which have superior characteristics in terms of a viewing angle, response time, brightness, driving voltage, and response speed, and which produce full-color images.

[0004] In an example, an organic light-emitting device includes an anode, a cathode, and an organic layer disposed between the anode and the cathode, wherein the organic layer includes an emission layer. A hole transport region may be disposed between the anode and the emission layer, and an electron transport region may be disposed between the emission layer and the cathode. Holes provided from the anode may move toward the emission layer through the hole transport region, and electrons provided from the cathode may move toward the emission layer through the electron transport region. The holes and the electrons recombine in the emission layer to produce excitons. These excitons transit from an excited state to a ground state, thereby generating light.

[0005] Luminescent compounds may be used to monitor, sense, or detect a variety of biological materials including cells and proteins. An example of the luminescent compounds is a phosphorescent luminescent compound.

[0006] Various types of organic light emitting devices are known. However, there still remains a need in OLEDs having low driving voltage, high efficiency, high brightness, and long lifespan.

SUMMARY

[0007] Aspects of the present disclosure provide a novel organometallic compound, an organic light-emitting device including the same, and a diagnostic composition including the organometallic compound.

[0008] Additional aspects will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the presented embodiments.

[0009] An aspect of the present disclosure provides an organometallic compound represented by Formula 1:



[0010] In Formula 1,

[0011] M may be iridium (Ir), osmium (Os), titanium (Ti), hafnium (Hf), europium (Eu), rhodium (Rh), or ruthenium (Ru),


[0012] L<sub>1</sub> may be a ligand represented by Formula 2,

[0013] n<sub>1</sub> may be 1, 2, or 3, wherein when n<sub>1</sub> is 2 or more, two or more groups L<sub>1</sub> may be identical to or different from each other,

[0014] L<sub>2</sub> may be a monodentate ligand, a bidentate ligand, a tridentate ligand, or a tetradentate ligand,

[0015] n<sub>2</sub> may be 0, 1, 2, 3, or 4, wherein when n<sub>2</sub> is 2 or more, two or more groups L<sub>2</sub> may be identical to or different from each other, and

[0016] L<sub>1</sub> and L<sub>2</sub> may be different from each other,



Formula 2

[0017] In Formula 2,

[0018] X<sub>1</sub> and X<sub>21</sub> may each independently be C or N,

[0019] ring CY<sub>11</sub>, ring CY<sub>12</sub>, and ring CY<sub>21</sub> may each independently be a C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a C<sub>1</sub>-C<sub>30</sub> heterocyclic group, and ring CY<sub>11</sub> and ring CY<sub>12</sub> may be condensed with each other,

[0020] T<sub>1</sub> may be \*—N(R<sub>2</sub>)—\*, \*—B(R<sub>2</sub>)—\*, \*—P(R<sub>2</sub>)—\*, \*—C(R<sub>2</sub>)(R<sub>3</sub>)—\*, \*—Si(R<sub>2</sub>)(R<sub>3</sub>)—\*, \*—Ge(R<sub>2</sub>)(R<sub>3</sub>)—\*, \*—S—\*, \*—Se—\*, \*—O—\*, \*—C(=O)—\*, \*—S(=O)—\*, \*—S(=O)<sub>2</sub>—\*, \*—C(R<sub>2</sub>)=\*, \*—C(R<sub>2</sub>)—\*, \*—C(R<sub>2</sub>)=C(R<sub>3</sub>)—\*, \*—C(=S)—\*, or \*—C≡C—\*, wherein \* and \*' each indicate a binding site to a neighboring atom,

[0021] R<sub>1</sub> to R<sub>3</sub> and R<sub>21</sub> may each independently be hydrogen, deuterium, —F, —Cl, —Br, —I, —SF<sub>5</sub>, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> alkyl group, a substituted or unsubstituted C<sub>2</sub>-C<sub>60</sub> alkenyl group, a substituted or unsubstituted C<sub>2</sub>-C<sub>60</sub> alkynyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> alkoxy group, a substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> heterocycloalkyl group, a substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> heterocycloalkenyl group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> aryl group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> aryloxy group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> arylthio group, a substituted or unsubstituted C<sub>7</sub>-C<sub>60</sub> heteroalkyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> het-

heteroaryl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> heteroarylthio group, a substituted or unsubstituted C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>1</sub>)(Q<sub>2</sub>), —Si(Q<sub>3</sub>)(Q<sub>4</sub>)(Q<sub>5</sub>), —Ge(Q<sub>3</sub>)(Q<sub>4</sub>)(Q<sub>5</sub>), —B(Q<sub>6</sub>)(Q<sub>7</sub>), —P(=O)(Q<sub>8</sub>)(Q<sub>9</sub>), —P(Q<sub>8</sub>)(Q<sub>9</sub>), or any combination thereof;

**[0022]** a1 and a21 may each independently be an integer from 0 to 20,

**[0023]** two or more of a plurality of groups R<sub>1</sub> may optionally be linked to form a C<sub>5</sub>-C<sub>30</sub> carbocyclic group that is unsubstituted or substituted with at least one R<sub>10a</sub> or a C<sub>1</sub>-C<sub>30</sub> heterocyclic group that is unsubstituted or substituted with at least one R<sub>10a</sub>,

**[0024]** two or more of a plurality of groups R<sub>21</sub> may optionally be linked to form a C<sub>5</sub>-C<sub>30</sub> carbocyclic group that is unsubstituted or substituted with at least one R<sub>10a</sub> or a C<sub>1</sub>-C<sub>30</sub> heterocyclic group that is unsubstituted or substituted with at least one R<sub>10a</sub>,

**[0025]** two or more of R<sub>1</sub> to R<sub>3</sub> and R<sub>21</sub> may optionally be linked to form a C<sub>5</sub>-C<sub>30</sub> carbocyclic group that is unsubstituted or substituted with at least one R<sub>10a</sub> or a C<sub>1</sub>-C<sub>30</sub> heterocyclic group that is unsubstituted or substituted with at least one R<sub>10a</sub>,

**[0026]** R<sub>10a</sub> is the same as defined in connection with R<sub>21</sub>,

**[0027]** \* and \*' each indicate a binding site to M in Formula 1, and

**[0028]** a substituent(s) of the substituted C<sub>1</sub>-C<sub>60</sub> alkyl group, the substituted C<sub>2</sub>-C<sub>60</sub> alkenyl group, the substituted C<sub>2</sub>-C<sub>60</sub> alkynyl group, the substituted C<sub>1</sub>-C<sub>60</sub> alkoxy group, the substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, the substituted C<sub>1</sub>-C<sub>60</sub> heterocycloalkyl group, the substituted C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, the substituted C<sub>1</sub>-C<sub>60</sub> heterocycloalkenyl group, the substituted C<sub>6</sub>-C<sub>60</sub> aryl group, the substituted C<sub>6</sub>-C<sub>60</sub> aryloxy group, the substituted C<sub>6</sub>-C<sub>60</sub> arylthio group, the substituted C<sub>7</sub>-C<sub>60</sub> arylalkyl group, the substituted C<sub>1</sub>-C<sub>60</sub> heteroaryl group, the substituted C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group, the substituted C<sub>1</sub>-C<sub>60</sub> heteroarylthio group, the substituted C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may each independently be:

**[0029]** deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, or a C<sub>1</sub>-C<sub>60</sub> alkoxy group;

**[0030]** a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, or a C<sub>1</sub>-C<sub>60</sub> alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>7</sub>-C<sub>60</sub> arylalkyl group, a C<sub>1</sub>-C<sub>60</sub>

heteroaryl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group, a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group, a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>11</sub>)(Q<sub>12</sub>), —Si(Q<sub>13</sub>)(Q<sub>14</sub>)(Q<sub>15</sub>), —Ge(Q<sub>13</sub>)(Q<sub>14</sub>)(Q<sub>15</sub>), —B(Q<sub>16</sub>)(Q<sub>17</sub>), —P(=O)(Q<sub>18</sub>)(Q<sub>19</sub>), —P(Q<sub>18</sub>)(Q<sub>19</sub>), or any combination thereof;

**[0031]** a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>7</sub>-C<sub>60</sub> arylalkyl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group, a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group, a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, or a monovalent non-aromatic condensed heteropolycyclic group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, a C<sub>1</sub>-C<sub>60</sub> alkoxy group, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>7</sub>-C<sub>60</sub> arylalkyl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group, a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group, a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>21</sub>)(Q<sub>22</sub>), —Si(Q<sub>23</sub>)(Q<sub>24</sub>)(Q<sub>25</sub>), —Ge(Q<sub>23</sub>)(Q<sub>24</sub>)(Q<sub>25</sub>), —B(Q<sub>26</sub>)(Q<sub>27</sub>), —P(=O)(Q<sub>28</sub>)(Q<sub>29</sub>), —P(Q<sub>28</sub>)(Q<sub>29</sub>), or any combination thereof;

**[0032]** —N(Q<sub>31</sub>)(Q<sub>32</sub>), —Si(Q<sub>33</sub>)(Q<sub>34</sub>)(Q<sub>35</sub>), —Ge(Q<sub>33</sub>)(Q<sub>34</sub>)(Q<sub>35</sub>), —B(Q<sub>36</sub>)(Q<sub>37</sub>), —P(=O)(Q<sub>38</sub>)(Q<sub>39</sub>), or —P(Q<sub>38</sub>)(Q<sub>39</sub>); or

**[0033]** any combination thereof, and

**[0034]** Q<sub>1</sub> to Q<sub>9</sub>, Q<sub>11</sub> to Q<sub>19</sub>, Q<sub>21</sub> to Q<sub>29</sub>, and Q<sub>31</sub> to Q<sub>39</sub> may each independently be hydrogen; deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; an amino group; a guanidino group; an amidino group; a hydrazino group; a hydrazono group; a carboxylic acid group or a salt thereof; a sulfonic acid group or a salt thereof; a phosphoric acid group or a salt thereof; a C<sub>1</sub>-C<sub>60</sub> alkyl group unsubstituted or substituted with deuterium, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, or any combination thereof; a C<sub>2</sub>-C<sub>60</sub> alkenyl group; a C<sub>2</sub>-C<sub>60</sub> alkynyl group; a C<sub>1</sub>-C<sub>60</sub> alkoxy group; a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group; a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group; a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group; a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group; a C<sub>6</sub>-C<sub>60</sub> aryl group unsubstituted or substituted with deuterium, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, or any combination thereof; a C<sub>6</sub>-C<sub>60</sub> aryloxy group; a C<sub>6</sub>-C<sub>60</sub> arylthio group; a C<sub>7</sub>-C<sub>60</sub> arylalkyl group; a C<sub>1</sub>-C<sub>60</sub> heteroaryl group; a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group; a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group; a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group; a monovalent non-aromatic condensed polycyclic group; or a monovalent non-aromatic condensed heteropolycyclic group.

**[0035]** Another aspect of the present disclosure provides an organic light-emitting device including:

**[0036]** a first electrode;

**[0037]** a second electrode; and

[0038] an organic layer disposed between the first electrode and the second electrode,

[0039] wherein the organic layer includes an emission layer, and

[0040] wherein the organic layer includes at least one organometallic compound represented by Formula 1.

[0041] Another aspect of the present disclosure provides a diagnostic composition including at least one organometallic compound represented by Formula 1.

#### BRIEF DESCRIPTION OF THE DRAWING

[0042] These and/or other aspects will become apparent and more readily appreciated from the following description of the embodiments, taken in conjunction with the FIGURE which is a schematic view of an organic light-emitting device according to an embodiment.

#### DETAILED DESCRIPTION

[0043] Reference will now be made in detail to embodiments, examples of which are illustrated in the accompanying drawings, wherein like reference numerals refer to like elements throughout. In this regard, the present embodiments may have different forms and should not be construed as being limited to the descriptions set forth herein. Accordingly, the embodiments are merely described below, by referring to the FIGURES, to explain aspects of the present description. As used herein, the term “and/or” includes any and all combinations of one or more of the associated listed items. Expressions such as “at least one of,” when preceding a list of elements, modify the entire list of elements and do not modify the individual elements of the list.

[0044] It will be understood that when an element is referred to as being “on” another element, it can be directly in contact with the other element or intervening elements may be present therebetween. In contrast, when an element is referred to as being “directly on” another element, there are no intervening elements present.

[0045] It will be understood that, although the terms first, second, third etc. may be used herein to describe various elements, components, regions, layers, and/or sections, these elements, components, regions, layers, and/or sections should not be limited by these terms. These terms are only used to distinguish one element, component, region, layer, or section from another element, component, region, layer, or section. Thus, a first element, component, region, layer, or section discussed below could be termed a second element, component, region, layer, or section without departing from the teachings of the present embodiments.

[0046] The terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. As used herein, the singular forms “a,” “an,” and “the” are intended to include the plural forms as well, unless the context clearly indicates otherwise.

[0047] The term “or” means “and/or.” It will be further understood that the terms “comprises” and/or “comprising,” or “includes” and/or “including” when used in this specification, specify the presence of stated features, regions, integers, steps, operations, elements, and/or components, but do not preclude the presence or addition of one or more other features, regions, integers, steps, operations, elements, components, and/or groups thereof.

[0048] Unless otherwise defined, all terms (including technical and scientific terms) used herein have the same mean-

ing as commonly understood by one of ordinary skill in the art to which this general inventive concept belongs. It will be further understood that terms, such as those defined in commonly used dictionaries, should be interpreted as having a meaning that is consistent with their meaning in the context of the relevant art and the present disclosure, and will not be interpreted in an idealized or overly formal sense unless expressly so defined herein.

[0049] Exemplary embodiments are described herein with reference to cross section illustrations that are schematic illustrations of idealized embodiments. As such, variations from the shapes of the illustrations as a result, for example, of manufacturing techniques and/or tolerances, are to be expected. Thus, embodiments described herein should not be construed as limited to the particular shapes of regions as illustrated herein but are to include deviations in shapes that result, for example, from manufacturing. For example, a region illustrated or described as flat may, typically, have rough and/or nonlinear features. Moreover, sharp angles that are illustrated may be rounded. Thus, the regions illustrated in the figures are schematic in nature and their shapes are not intended to illustrate the precise shape of a region and are not intended to limit the scope of the present claims.

[0050] “About” or “approximately” as used herein is inclusive of the stated value and means within an acceptable range of deviation for the particular value as determined by one of ordinary skill in the art, considering the measurement in question and the error associated with measurement of the particular quantity (i.e., the limitations of the measurement system). For example, “about” can mean within one or more standard deviations, or within  $\pm 30\%$ ,  $20\%$ ,  $10\%$ ,  $5\%$  of the stated value.


[0051] An aspect of the present disclosure provides an organometallic compound represented by Formula 1 below:



[0052] In Formula 1, M may be iridium (Ir), osmium (Os), titanium (Ti), hafnium (Hf), europium (Eu), rhodium (Rh), or ruthenium (Ru).

[0053] In an exemplary embodiment, M may be Ir, but embodiments of the present disclosure are not limited thereto.

[0054] In Formula 1,  $L_1$  may be a ligand represented by Formula 2:



[0055] Formula 2 will be understood by referring to a detailed description thereof provided below.

**[0056]** In Formula 1,  $n_1$  indicates the number of groups  $L_1$ , and may be 1, 2, or 3. When  $n_1$  is 2 or more, two or more groups  $L_1$  may be identical to or different from each other.

**[0057]** In Formula 1,  $L_2$  may be a monodentate ligand, a bidentate ligand, a tridentate ligand, or a tetradentate ligand.  $L_2$  will be understood by referring to a detailed description thereof provided below.

**[0058]** In Formula 1,  $n_2$  indicates the number of groups  $L_2$ , and may be 0, 1, 2, 3, or 4. When  $n_2$  is 2 or more, two or more groups  $L_2$  may be identical to or different from each other.

**[0059]** In Formula 1,  $L_1$  and  $L_2$  may be different from each other. Thus, when  $n_2$  in Formula 1 is not 0, the organometallic compound represented by Formula 1 may be a heteroleptic complex.

**[0060]** In an embodiment, in Formula 1, i) M may be Ir or Os, and the sum of  $n_1$  and  $n_2$  may be 3 or 4; or ii) M may be Pt, and the sum of  $n_1$  and  $n_2$  may be 2.

**[0061]** In one or more embodiments,  $n_2$  in Formula 1 may be 1 or 2.

**[0062]** In Formula 2,  $X_1$  and  $X_{21}$  may each independently be C or N.

**[0063]** In an exemplary embodiment,  $X_1$  may be N, and  $X_{21}$  may be C, but embodiments of the present disclosure are not limited thereto.

**[0064]** In Formula 2, a bond between  $X_1$  and M in Formula 1 may be a coordinate bond, and a bond between  $X_{21}$  and M in Formula 1 may be a covalent bond. In this regard, the organometallic compound represented by Formula 1 may be electrically neutral.

**[0065]** In Formula 2, ring  $CY_{11}$ , ring  $CY_{12}$ , and ring  $CY_{21}$  may each independently be a  $C_5$ - $C_{30}$  carbocyclic group or a  $C_1$ - $C_{30}$  heterocyclic group. Ring  $CY_{11}$  and ring  $CY_{12}$  may be condensed with each other.

**[0066]** In one or more embodiments, ring  $CY_{11}$ , ring  $CY_{12}$ , and ring  $CY_{21}$  may each independently be i) a first ring, ii) a second ring, iii) a condensed ring in which two or more first rings are condensed with each other, iv) a condensed ring in which two or more second rings are condensed with each other, or v) a condensed ring in which one or more first rings are condensed with one or more second rings.

**[0067]** The first ring may be a cyclopentane group, a cyclopentadiene group, a furan group, a thiophene group, a pyrrole group, a silole group, an indene group, a benzofuran group, a benzothiophene group, an indole group, a benzosilole group, an oxazole group, an isoxazole group, an oxadiazole group, an isoxadiazole group, an oxatriazole group, an isoxatriazole group, a thiazole group, an isothiazole group, a thiadiazole group, an isothiadiazole group, a thiatriazole group, an isothiatriazole group, a pyrazole group, an imidazole group, a triazole group, a tetrazole group, an azasilole group, a diazasilole group, or a triazasilole group.

**[0068]** The second ring may be an adamantane group, a norbornane group, a norbornene group, a bicyclo[1.1.1]pentane group, a bicyclo[2.1.1]hexane group, a bicyclo[2.2.1]heptane group, a bicyclo[2.2.2]octane group, a cyclohexane group, a cyclohexene group, a benzene group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, or a triazine group.

**[0069]** In an embodiment, ring  $CY_{11}$ , ring  $CY_{12}$ , and ring  $CY_{21}$  may each independently be a cyclopentene group, a cyclohexene group, a cycloheptene group, a benzene group,

a naphthalene group, an anthracene group, a fluoranthene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a 1,2,3,4-tetrahydronaphthalene group, a pyrrole group, a borole group, a phosphole group, a cyclopentadiene group, a silole group, a germole group, a thiophene group, a selenophene group, a furan group, an indole group, a benzoborole group, a benzophosphole group, an indene group, a benzosilole group, a benzogermole group, a benzothiophene group, a benzoselenophene group, a benzofuran group, a carbazole group, a dibenzoborole group, a dibenzophosphole group, a fluorene group, a dibenzosilole group, a dibenzogermole group, a dibenzothiophene group, a dibenzoselenophene group, a dibenzofuran group, a dibenzothiophene 5-oxide group, a 9H-fluorene-9-one group, a dibenzothiophene 5,5-dioxide group, an azaindole group, an azabenzoborole group, an azabenzophosphole group, an azaindene group, an azabenzosilole group, an azabenzogermole group, an azabenzothiophene group, an azabenzoselenophene group, an azabenzofuran group, an azacarbazole group, an azadibenzoborole group, an azadibenzophosphole group, an azafluorene group, an azadibenzosilole group, an azadibenzogermole group, an azadibenzothiophene group, an azadibenzoselenophene group, an azadibenzofuran group, an azadibenzothiophene 5-oxide group, an aza-9H-fluorene-9-one group, an azadibenzothiophene 5,5-dioxide group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a benzoisoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrazole group, an imidazole group, a triazole group, an azaborole group, an azaphosphole group, an azacyclopentadiene group, an azasilole group, an azagermole group, an azaselenophene group, an oxazole group, an isooxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, or a 5,6,7,8-tetrahydroquinoline group, but embodiments of the present disclosure are not limited thereto.

**[0070]** In an embodiment, ring  $CY_{11}$  may be a pyridine group, a quinoline group, an isoquinoline group, a benzoquinoline group, or a benzoisoquinoline group; and/or ring  $CY_{12}$  may be a benzene group, a naphthalene group, a phenanthrene group, a pyrrole group, a borole group, a phosphole group, a cyclopentadiene group, a silole group, a germole group, a thiophene group, a selenophene group, a furan group, a pyrazole group, an imidazole group, an azaborole group, an azaphosphole group, an azacyclopentadiene group, an azasilole group, an azagermole group, an azaselenophene group, an oxazole group, an isooxazole group, a thiazole group, or an isothiazole group; and/or ring  $CY_{21}$  may be a benzene group, a pyridine group, a pyrimidine group, a naphthalene group, a fluorene group, a carbazole group, a benzofuran group, a benzothiophene group, or dibenzosilole group, but embodiments of the present disclosure are not limited thereto.

**[0071]** In Formula 2,  $T_1$  may be  $*-N(R_2)-*$ ,  $*-B(R_2)-*$ ,  $*-P(R_2)-*$ ,  $*-C(R_2)(R_3)-*$ ,  $*-Si(R_2)(R_3)-*$ ,  $*-Ge(R_2)(R_3)-*$ ,  $*-S-*$ ,  $*-Se-*$ ,  $*-O-*$ ,  $*-C(=O)-*$ ,  $*-S(=O)-*$ ,  $*-S(=O)_2-*$ ,  $*-C(R_2)=*$ ,  $*=C(R_2)-*$ ,  $*-C(R_2)-C(R_3)-*$ ,  $*-C(=S)-*$ , or  $*-C=C-*$ , wherein  $*$  and  $*'$  each

indicate a binding site to a neighboring atom.  $R_2$  and  $R_3$  will be understood by referring to a detailed description thereof provided below.  $R_2$  and  $R_3$  may optionally, be linked via a single bond, a double bond,  $*-N(R_4)-*$ ,  $*-B(R_4)-*$ ,  $*-P(R_4)-*$ ,  $*-C(R_4)(R_5)-*$ ,  $*-Si(R_4)(R_5)-*$ ,  $*-Ge(R_4)(R_5)-*$ ,  $*-S-*$ ,  $*-Se-*$ ,  $*-O-*$ ,  $*C(=O)-*$ ,  $*-S(=O)-*$ ,  $*-S(=O)_2-*$ ,  $*-C(R_4)=*$ ,  $*-C(R_4)-*$ ,  $*-C(R_4)=C(R_5)-*$ ,  $*-C(=S)-*$ , or  $*-C\equiv C-*$  to form a  $C_5-C_{30}$  carbocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$  or a  $C_1-C_{30}$  heterocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$ .  $R_{10a}$  is the same as defined in connection with  $R_{21}$ . The  $C_5-C_{30}$  carbocyclic group and the  $C_1-C_{30}$  heterocyclic group are each the same as defined in connection with ring  $CY_{21}$ .

**[0072]** In an embodiment,  $T_1$  in Formula 2 may be  $*-O-*$ .

**[0073]**  $R_1$  to  $R_3$  and  $R_{21}$  may each independently be hydrogen, deuterium,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-I$ ,  $-SF_5$ , a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted  $C_1-C_{60}$  alkyl group, a substituted or unsubstituted  $C_2-C_{60}$  alkenyl group, a substituted or unsubstituted  $C_2-C_{60}$  alkynyl group, a substituted or unsubstituted  $C_1-C_{60}$  alkoxy group, a substituted or unsubstituted  $C_3-C_{10}$  cycloalkyl group, a substituted or unsubstituted  $C_1-C_{60}$  heterocycloalkyl group, a substituted or unsubstituted  $C_3-C_{10}$  cycloalkenyl group, a substituted or unsubstituted  $C_1-C_{10}$  heterocycloalkenyl group, a substituted or unsubstituted  $C_6-C_{60}$  aryl group, a substituted or unsubstituted  $C_6-C_{60}$  aryloxy group, a substituted or unsubstituted  $C_6-C_{60}$  arylthio group, a substituted or unsubstituted  $C_1-C_{60}$  heteroaryl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group,  $-N(Q_1)(Q_2)$ ,  $-Si(Q_3)(Q_4)(Q_5)$ ,  $-Ge(Q_3)(Q_4)(Q_5)$ ,  $-B(Q_6)(Q_7)$ ,  $-P(=O)(Q_8)(Q_9)$ , or  $-P(Q_8)(Q_9)$ , wherein  $Q_1$  to  $Q_9$  will be understood by referring to a detailed description thereof provided below.

**[0074]** In an embodiment,  $R_1$  to  $R_3$  and  $R_{21}$  may each independently be:

hydrogen, deuterium,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-I$ , a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof,  $-SF_5$ ,  $C_1-C_{20}$  alkyl group, or a  $C_1-C_{20}$  alkoxy group;

**[0075]** a  $C_1-C_{20}$  alkyl group and a  $C_1-C_{20}$  alkoxy group, each substituted with deuterium,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-I$ ,  $-CD_3$ ,  $-CD_2H$ ,  $-CDH_2$ ,  $-CF_3$ ,  $-CF_2H$ ,  $-CFH_2$ , a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_1-C_{10}$  alkyl group, a  $C_1-C_{20}$  alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantyl group, a norbornyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, a  $(C_1-C_{20})$  alkyl)cyclopentyl group, a  $(C_1-C_{20})$  alkyl)cyclohexyl group, a  $(C_1-C_{20})$  alkyl)cycloheptyl group, a  $(C_1-C_{20})$  alkyl)cyclooctyl group, a  $(C_1-C_{20})$  alkyl)adamantanyl group, a  $(C_1-C_{20})$  alkyl)norbornanyl group, a  $(C_1-C_{20})$  alkyl)norbornenyl group, a  $(C_1-C_{20})$  alkyl)cyclopentenyl group, a  $(C_1-C_{20})$  alkyl)cyclohexenyl group, a  $(C_1-C_{20})$  alkyl)cycloheptenyl group, a  $(C_1-C_{20})$  alkyl)bicyclo[1.1.1]pentyl group, a  $(C_1-C_{20})$  alkyl)bicyclo[2.1.1]hexyl group, a  $(C_1-C_{20})$  alkyl)bicyclo[2.2.1]heptyl group, a  $(C_1-C_{20})$  alkyl)bicyclo[2.2.2]octyl group, a phenyl group, a  $(C_1-C_{20})$  alkyl)phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthra-

cycloheptyl group, a  $(C_1-C_{20})$  alkyl)cyclooctyl group, a  $(C_1-C_{20})$  alkyl)adamantanyl group, a  $(C_1-C_{20})$  alkyl)norbornanyl group, a  $(C_1-C_{20})$  alkyl)norbornenyl group, a  $(C_1-C_{20})$  alkyl)cyclopentenyl group, a  $(C_1-C_{20})$  alkyl)cyclohexenyl group, a  $(C_1-C_{20})$  alkyl)cycloheptenyl group, a  $(C_1-C_{20})$  alkyl)bicyclo[1.1.1]pentyl group, a  $(C_1-C_{20})$  alkyl)bicyclo[2.1.1]hexyl group, a  $(C_1-C_{20})$  alkyl)bicyclo[2.2.1]heptyl group, a  $(C_1-C_{20})$  alkyl)bicyclo[2.2.2]octyl group, a phenyl group, a  $(C_1-C_{20})$  alkyl)phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a pyridinyl group, a pyrimidinyl group, or any combination thereof;

**[0076]** a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantyl group, a norbornyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, a phenyl group, a  $(C_1-C_{20})$  alkyl)phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthroline group, a benzimidazolyl group, a benzofuran group, a benzothio-phenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetra-zolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuran group, a dibenzothiophenyl group, a benzo-carbazolyl group, a dibenzocarbazolyl group, an imida-zopyridinyl group, an imidazopyrimidinyl group, an azac-arbazolyl group, an azadibenzofuran group, or an azadibenzothiophenyl group, each unsubstituted or substituted with deuterium,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-I$ ,  $-CD_3$ ,  $-CD_2H$ ,  $-CDH_2$ ,  $-CF_3$ ,  $-CF_2H$ ,  $-CFH_2$ , a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_1-C_{20}$  alkyl group, a deuterium-containing  $C_2-C_{20}$  alkyl group, a  $C_1-C_{20}$  alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantyl group, a norbornyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, a  $(C_1-C_{20})$  alkyl)cyclopentyl group, a  $(C_1-C_{20})$  alkyl)cyclohexyl group, a  $(C_1-C_{20})$  alkyl)cycloheptyl group, a  $(C_1-C_{20})$  alkyl)cyclooctyl group, a  $(C_1-C_{20})$  alkyl)adamantanyl group, a  $(C_1-C_{20})$  alkyl)norbornanyl group, a  $(C_1-C_{20})$  alkyl)norbornenyl group, a  $(C_1-C_{20})$  alkyl)cyclopentenyl group, a  $(C_1-C_{20})$  alkyl)cyclohexenyl group, a  $(C_1-C_{20})$  alkyl)cycloheptenyl group, a  $(C_1-C_{20})$  alkyl)bicyclo[1.1.1]pentyl group, a  $(C_1-C_{20})$  alkyl)bicyclo[2.1.1]hexyl group, a  $(C_1-C_{20})$  alkyl)bicyclo[2.2.1]heptyl group, a  $(C_1-C_{20})$  alkyl)bicyclo[2.2.2]octyl group, a phenyl group, a  $(C_1-C_{20})$  alkyl)phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthra-

cenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranyl group, an azadibenzothiophenyl group, or any combination thereof; or

**[0077]** —N(Q<sub>1</sub>)(Q<sub>2</sub>), —Si(Q<sub>3</sub>)(Q<sub>4</sub>)(Q<sub>5</sub>), —Ge(Q<sub>3</sub>)(Q<sub>4</sub>)(Q<sub>5</sub>), —B(Q<sub>6</sub>)(Q<sub>7</sub>), —P(=O)(Q<sub>8</sub>)(Q<sub>9</sub>), or —P(Q<sub>8</sub>)(Q<sub>9</sub>), and

**[0078]** Q<sub>1</sub> to Q<sub>9</sub> may each independently be:

**[0079]** —CH<sub>3</sub>, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CH<sub>2</sub>CH<sub>3</sub>, —CH<sub>2</sub>CD<sub>3</sub>, —CH<sub>2</sub>CD<sub>2</sub>H, —CH<sub>2</sub>CDH<sub>2</sub>, —CHDCCH<sub>3</sub>, —CHDCD<sub>2</sub>H, —CHDCDH<sub>2</sub>, —CHDCD<sub>3</sub>, —CD<sub>2</sub>CH<sub>3</sub>, —CD<sub>2</sub>CD<sub>3</sub>, —CD<sub>2</sub>CD<sub>2</sub>H, or —CD<sub>2</sub>CDH<sub>2</sub>; or

**[0080]** an n-propyl group, an iso-propyl group, an n-butyl group, a sec-butyl group, an iso-butyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neo-pentyl group, an iso-pentyl group, a sec-pentyl group, a 3-pentyl group, a sec-iso-pentyl group, a phenyl group, a biphenyl group or a naphthyl group, each unsubstituted or substituted with deuterium, a C<sub>1</sub>-C<sub>10</sub> alkyl group, a phenyl group, or any combination thereof,


**[0081]** but embodiments of the present disclosure are not limited thereto.

**[0082]** In one or more embodiments, R<sub>1</sub> to R<sub>3</sub> and R<sub>21</sub> may each independently be hydrogen, deuterium, —F, a cyano group, a nitro group, —SF<sub>5</sub>, —CH<sub>3</sub>, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a group represented by one of Formulae 9-1 to 9-66, a group represented by one of Formulae 9-1 to 9-66 in which at least one hydrogen is substituted with deuterium, a group represented by one of Formulae 10-1 to 10-118, a group represented by one of Formulae 10-1 to 10-118 in which at least one hydrogen is substituted with deuterium, a group represented by one of Formulae 10-201 to 10-342, a group represented by one of Formulae 10-201 to 10-342 in which at least one hydrogen is substituted with deuterium, —Si(Q<sub>3</sub>)(Q<sub>4</sub>)(Q<sub>5</sub>), or —Ge(Q<sub>3</sub>)(Q<sub>4</sub>)(Q<sub>5</sub>) (wherein detailed descriptions of Q<sub>3</sub> to Q<sub>5</sub> are the same as described above), but embodiments of the present disclosure are not limited thereto:

-continued




9-1




9-2




9-3



9-4




9-5




9-6




9-7




9-8




9-9




9-10



9-11




9-12




9-13




9-14




9-15



9-16
















9-17




9-18

-continued




-continued

9-19




9-32

9-20




9-33

9-21



9-34

9-22




9-35

9-23




9-36

9-24




9-37

9-25



9-38

9-26



9-39

9-27




9-40

9-28




9-41

9-29




9-42

9-30



9-43


9-31




-continued




9-44




9-45




9-46




9-47




9-48




9-49




9-50



9-51




9-52




9-53


-continued




9-54




9-55




9-56




9-57




9-58




9-59



9-60













9-61




9-62

-continued




-continued

9-63




10-8

9-64




10-9

9-65




10-10

9-66




10-11

10-1




10-12

10-2




10-13

10-3




10-14

10-4




10-15

10-5




10-16

10-6













10-17

10-7




10-18

-continued




-continued

10-19




10-29

10-20




10-30

10-21




10-31

10-22




10-32

10-23




10-33

10-24




10-34

10-25




10-35

10-26




10-36

10-27












10-37

10-28




10-38

-continued




-continued

10-39




10-48

10-40




10-49

10-41




10-50

10-42




10-51

10-43




10-52

10-44



10-53


10-45



10-54









10-46

10-47




10-55

-continued




-continued

10-56




10-64

10-57




10-65

10-58




10-66

10-59




10-67

10-60




10-68

10-61




10-69

10-62




10-70

10-63




10-71




10-72

-continued




10-73


-continued




10-80




10-74




10-81




10-75




10-82




10-76




10-83




10-77




10-84



10-78




10-85




10-79

-continued




10-86


-continued




10-93




10-87




10-94




10-88




10-95




10-89




10-96




10-90




10-97




10-91



10-98












10-92




10-99

-continued




-continued

10-100




10-109

10-101



10-110

10-102



10-111

10-103


10-104

10-105


10-106

10-107


10-108



10-112




10-113




10-114


-continued




10-115




10-116




10-117



10-118




10-201




10-202


-continued




10-203




10-204




10-205




10-206



10-207














10-208




10-209

-continued




-continued

10-210




10-221

10-211




10-222

10-212




10-223

10-213




10-224

10-214




10-225

10-215




10-226

10-216




10-227

10-217




10-228

10-218




10-229

10-219










10-230

10-220




10-231

-continued




-continued

10-232




10-239

10-233




10-240

10-234




10-241

10-235




10-242

10-236




10-243

10-237










10-244

10-238




10-245

-continued




-continued

10-246




10-253

10-247




10-254

10-248




10-255

10-249




10-256

10-250




10-257

10-251










10-258

10-252




10-259

-continued




-continued

10-260




10-267

10-261




10-268

10-262




10-269

10-263




10-270

10-264




10-271

10-265












10-272

10-266




10-273


-continued




10-274




10-275




10-276




10-277




10-278




10-279





10-280



10-281



10-282



-continued

10-283

10-284

10-285

10-286

10-287

10-288

10-289

10-290














10-291

10-292

10-293


10-294

-continued




-continued

10-295




10-296




10-297

10-298




10-299

10-300




10-301

10-302




10-303


10-304



10-305



10-306



10-307

10-308

10-309

10-310


10-311

10-312


10-313

10-314


-continued




10-315




10-316




10-317




10-318



10-319




10-320




10-321


-continued




10-322




10-323




10-324




10-325



10-326




10-327




10-328


-continued




10-329




10-336




10-330




10-337




10-331




10-338




10-332




10-339




10-340




10-341



10-333



10-342



10-335

-continued

**[0083]** In Formulae 9-1 to 9-66, 10-1 to 10-118 and 10-201 to 10-342, \* indicates a binding site to a neighboring atom, Ph indicates a phenyl group, or TMS indicates a trimethylsilyl group.


**[0084]** In an exemplary embodiment, Formula 9-33 may be a branched C<sub>6</sub> alkyl group and a tert-butyl group substituted with two methyl groups.

**[0085]** The “group represented by one of Formulae 9-1 to 9-66 in which at least one hydrogen is substituted with deuterium” may be, for example, a group represented by one of Formulae 9-501 to 9-514 and 9-601 to 9-638:




9-501










-continued



-continued




-continued




-continued

9-609




9-618

9-610




9-619

9-611




9-620

9-612




9-621

9-613




9-622

9-614




9-623

9-615




9-624

9-616




9-625

9-617




9-626


-continued




9-627




9-628




9-629




9-630




9-631




9-632




9-633



9-634




9-635




9-636

-continued




9-637




9-638


**[0086]** The “group represented by one of Formulae 10-1 to 10-118 in which at least one hydrogen is substituted with deuterium” may be, for example, a group represented by one of Formulae 10-501 to 10-546:




10-501




10-502




10-503




10-504



10-505












10-506




10-507

-continued




-continued

10-508




10-509

10-510




10-511


10-512




10-513





10-514



10-515



10-516



10-517

10-518

10-519

10-520


10-521

10-522


10-523

10-524


-continued




10-525




10-526




10-527




10-528




10-529



10-530




10-531




10-532


-continued




10-533




10-534




10-535




10-536



10-537




10-538




10-540


-continued




10-541




10-542




10-543



10-544



10-545



10-546

**[0087]** In Formula 2, a1 and a21 each indicate the number of groups  $R_1$  and the number of groups  $R_{21}$ , respectively, and may each independently be an integer from 0 to 20. When a1 is 2 or more, two or more groups  $R_1$  may be identical or different from each other, and when a21 is 2 or more, two or more groups  $R_{21}$  may be identical to or different from each other. For example, a1 and a21 may each independently be an integer from 0 to 10, but embodiments of the present disclosure are not limited thereto.

**[0088]** In an embodiment, i) two or more of a plurality of groups R, in Formula 2 may optionally be linked to form a  $C_5$ - $C_{30}$  carbocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$  or a  $C_1$ - $C_{30}$  heterocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$ ; ii) two or more of a plurality of groups  $R_{21}$  in Formula 2 may option-

ally be linked to form a  $C_5$ - $C_{30}$  carbocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$  or a  $C_1$ - $C_{30}$  heterocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$ ; or iii) two or more of  $R_1$  to  $R_5$  and  $R_{21}$  in Formula 2 may optionally be linked to form a  $C_5$ - $C_{30}$  carbocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$  or a  $C_1$ - $C_{30}$  heterocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$ . Here, "a  $C_5$ - $C_{30}$  carbocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$  or a  $C_1$ - $C_{30}$  heterocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$ " may be, for example, an adamantane group, a norbornane group, a norbornene group, a bicyclo[1.1.1]pentane group, a bicyclo[2.1.1]hexane group, a bicyclo[2.2.1]heptane group, a bicyclo[2.2.2]octane group, a cyclopentane group, a cyclohexane group, a cycloheptane group, a cyclopentene group, a cyclohexene group, a cycloheptene group, a benzene group, a naphthalene group, an anthracene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a 1,2,3,4-tetrahydronaphthalene group, a pyrrole group, a borole group, a phosphole group, a cyclopentadiene group, a silole group, a germole group, a thiophene group, a selenophene group, a furan group, an indole group, a benzoborole group, a benzophosphole group, an indene group, a benzosilole group, a benzogermole group, a benzothiophene group, a benzoselenophene group, a benzofuran group, a carbazole group, a dibenzoborole group, a dibenzophosphole group, a fluorene group, a dibenzosilole group, a dibenzogermole group, a dibenzothiophene group, a dibenzoselenophene group, a dibenzofuran group, a dibenzothiophene 5-oxide group, a 9H-fluorene-9-one group, a dibenzothiophene 5,5-dioxide group, an azaindole group, an azabenzoborole group, an azabenzophosphole group, an azaindene group, an azabenzosilole group, an azabenzogermole group, an azabenzothiophene group, an azabenzoselenophene group, an azabenzofuran group, an azacarbazole group, an azadibenzoborole group, an azadibenzophosphole group, an azafluorene group, an azadibenzosilole group, an azadibenzogermole group, an azadibenzothiophene group, an azadibenzoselenophene group, an azadibenzofuran group, an azadibenzothiophene 5-oxide group, an aza-9H-fluorene-9-one group, an azadibenzothiophene 5,5-dioxide group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a benzoisoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrazole group, an imidazole group, a triazole group, an azaborole group, an azaphosphole group, an azacyclopentadiene group, an azasilole group, an azagermole group, an azaselenophene group, an oxazole group, an isooxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, or a 5,6,7,8-tetrahydroquinoline group, each unsubstituted or substituted with at least one  $R_{10a}$ .

**[0089]** Non-limiting examples of the  $C_1$ - $C_{60}$  alkyl group, the  $C_1$ - $C_{20}$  alkyl group, and/or the  $C_1$ - $C_{10}$  alkyl group include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, a sec-isopentyl group, an


n-hexyl group, an isohexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an isoheptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an isooctyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an isononyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an isodecyl group, a sec-decyl group, or a tert-decyl group, each unsubstituted or substituted with a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, a sec-isopentyl group, an n-hexyl group, an isohexyl group, a sec-hexyl group, a tert-hexyl group, an n-heptyl group, an isoheptyl group, a sec-heptyl group, a tert-heptyl group, an n-octyl group, an isooctyl group, a sec-octyl group, a tert-octyl group, an n-nonyl group, an isononyl group, a sec-nonyl group, a tert-nonyl group, an n-decyl group, an isodecyl group, a sec-decyl group, a tert-decyl group, or any combination thereof, and the like, but embodiments of the present disclosure are not limited thereto.

**[0090]** Non-limiting examples of the C<sub>1</sub>-C<sub>60</sub> alkoxy group, C<sub>1</sub>-C<sub>20</sub> alkoxy group and/or C<sub>1</sub>-C<sub>10</sub> alkoxy group include a methoxy group, an ethoxy group, a propoxy group, a butoxy group, or a pentoxy group, and the like, but embodiments of the present disclosure are not limited thereto.


**[0091]** Non-limiting examples of the C<sub>3</sub>-C<sub>10</sub> cycloalkyl group include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantanyl group, a norbornanyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, and the like, but embodiments of the present disclosure are not limited thereto.

**[0092]** In Formula 2, \* and \*' each indicate a binding site to M in Formula 1.


**[0093]** In an embodiment, a group represented by



in Formula 2 may be a group represented by one of Formulae CY1-1 to CY1-69:




CY1-1




CY1-2


-continued




CY1-3




CY1-4




CY1-5




CY1-6




CY1-7



CY1-8










CY1-9



CY1-10




-continued




-continued

CY1-23




CY1-30

CY1-24




CY1-31

CY1-25




CY1-32

CY1-26




CY1-33

CY1-27




CY1-34

CY1-28




CY1-35


CY1-29



CY1-36




CY1-37




CY1-38

CY1-39


-continued




CY1-40




CY1-41




CY1-42




CY1-43



CY1-44




CY1-45




CY1-46


-continued




CY1-47




CY1-48




CY1-49




CY1-50



CY1-51










CY1-52




CY1-53

-continued




-continued

CY1-54




CY1-61

CY1-55




CY1-62

CY1-56




CY1-63

CY1-57




CY1-64

CY1-58




CY1-65

CY1-59




CY1-66

CY1-60




-continued




in Formula 2 may be a group represented by one of Formulae CY1(1) to CY1(165):

CY1-67




CY1(1)

CY1-68




CY1(2)


CY1-69




CY1(3)




CY1(4)




CY1(5)



CY1(6)




CY1(7)










CY1(8)

- [0094] In Formulae CY1-1 to CY1-69,
- [0095]  $X_1$  and  $R_1$  are the same as described above,
- [0096]  $X_{11}$  may be O, S, Se,  $N(R_{19})$ ,  $C(R_{19a})(R_{19b})$ , or  $Si(R_{19a})(R_{19b})$ ,
- [0097]  $R_{19}$ ,  $R_{19a}$ ,  $R_{19b}$ ,  $R_{1a}$  and  $R_{1b}$  may each be the same as defined in connection with  $R_1$ ,
- [0098] a18 may be an integer from 0 to 8,
- [0099] a16 may be an integer from 0 to 6,
- [0100] a15 may be an integer from 0 to 5,
- [0101] a14 may be an integer from 0 to 4,
- [0102] a13 may be an integer from 0 to 3,
- [0103] \*<sup>#</sup> indicates a binding site to  $T_1$  in Formula 2, and
- [0104] \*<sup>+</sup> indicates a binding site to M in Formula 1.
- [0105] In one or more embodiments, a group represented by






-continued




-continued


CY1(25)




CY1(26)




CY1(27)




CY1(28)



CY1(29)



CY1(30)



CY1(31)

CY1(32)

CY1(33)

CY1(34)








CY1(35)

CY1(36)

CY1(37)




-continued




-continued


CY1(50)




CY1(51)



CY1(52)




CY1(53)




CY1(54)

CY1(55)



CY1(56)



CY1(57)

CY1(58)

CY1(59)










CY1(60)

CY1(61)

CY1(62)




-continued




-continued

CY1(76)




CY1(77)




CY1(78)

CY1(79)




CY1(80)




CY1(81)


CY1(82)



CY1(83)



CY1(84)



CY1(85)

CY1(86)

CY1(87)

CY1(88)

CY1(89)








CY1(90)

CY1(91)






-continued




-continued


CY1(121)




CY1(122)




CY1(123)




CY1(124)




CY1(125)



CY1(126)



CY1(127)



CY1(128)

CY1(129)

CY1(130)







CY1(131)

CY1(132)

CY1(133)


CY1(134)

-continued




-continued

CY1(135)




CY1(141)

CY1(136)




CY1(142)

CY1(137)




CY1(143)

CY1(138)



CY1(144)






CY1(139)



CY1(145)


CY1(140)

-continued




-continued

CY1(146)




CY1(151)

CY1(147)




CY1(152)

CY1(148)




CY1(153)

CY1(149)









CY1(154)

CY1(150)




CY1(156)

-continued




-continued


CY1(157)



CY1(158)



CY1(159)



CY1(160)

[0106] In Formulae CY1(1) to CY1(165),

[0107]  $X_1$  and  $X_{11}$  are the same as described above,


[0108]  $R_{11}$  to  $R_{16}$  may each be the same as defined in connection with  $R_1$ , provided that,  $R_{11}$  to  $R_{16}$  are not hydrogen,

[0109] "\*" indicates a binding site to  $T_1$  in Formula 2, and

[0110] "\*" indicates a binding site to M in Formula 1.

CY1(161)

[0111] In one or more embodiments, a group represented by



CY1(162)


in Formula 2 may be a group represented by one of Formulae CY21-1 to CY21-25:

CY1(163)









CY1(164)

CY1(165)

CY21-1




-continued




-continued


CY21-2



CY21-3




CY21-4




CY21-5

CY21-6




CY21-7

CY21-8



CY21-9



CY21-10

CY21-11







CY21-12

CY21-13

CY21-14


CY21-15

-continued




-continued

CY21-16




CY21-22

CY21-17




CY21-23

CY21-18



CY21-24

CY21-19




CY21-25

CY21-20


- [0112] In Formulae CY21-1 to CY21-25,
- [0113]  $X_{21}$  and  $R_{21}$  are the same as described above,
- [0114]  $X_{22}$  may be  $C(R_{22})(R_{23})$ ,  $N(R_{22})$ ,  $O$ ,  $S$ , or  $Si(R_{22})(R_{23})$ ,
- [0115]  $R_{22}$  to  $R_{29}$  may each be the same as defined in connection with  $R_{21}$ ,
- [0116]  $a_{26}$  may be an integer from 0 to 6,
- [0117]  $a_{24}$  may be an integer from 0 to 4,
- [0118]  $a_{23}$  may be an integer from 0 to 3,
- [0119]  $a_{22}$  may be an integer from 0 to 2,
- [0120] \*\* indicates a binding site to  $T_1$  in Formula 2, and
- [0121] \* indicates a binding site to  $M$  in Formula 1.
- [0122] In one or more embodiments, a group represented by

CY21-21











in Formula 2 may be a group represented by one of Formulae CY21(1) to CY21(56) and CY21-20 to CY21-25:


-continued




-continued




CY21(17)




CY21(18)




CY21(19)




CY21(20)




CY21(21)




CY21(22)



CY21(23)



CY21(24)



-continued

CY21(25)

CY21(26)

CY21(27)

CY21(28)










CY21(29)

CY21(30)


CY21(31)

CY21(32)


-continued




CY21(33)




CY21(34)




CY21(35)




CY21(36)




CY21(37)



CY21(38)




CY21(39)



CY21(40)

CY21(41)



-continued

CY21(42)

CY21(43)

CY21(44)

CY21(45)


CY21(46)

CY21(47)

CY21(48)


CY21(49)

-continued



CY21(50)

**[0129]** In an embodiment,  $L_2$  in Formula 1 may be a bidentate ligand represented by Formula 3:




Formula 3

CY21(51)

**[0130]** In Formula 3,

**[0131]**  $X_{31}$  and  $X_{32}$  may each independently be O, S, Se, N, C, P, Si, or As,



CY21(52)



indicates a linking group linking  $X_{31}$  and  $X_{32}$  together, and


**[0132]** \* and \*' each indicate a binding site to M in Formula 1.

CY21(53)

**[0133]** In one or more embodiments, in Formula 3,  $X_{31}$  and  $X_{32}$  may each independently be O, S, Se, or N, but embodiments of the present disclosure are not limited thereto.


CY21(54)

**[0134]** In one or more embodiments, in Formula 3, i)  $X_{31}$  and  $X_{32}$  may each be O; or ii)  $X_{31}$  may be N, and  $X_{32}$  may be C, but embodiments of the present disclosure are not limited thereto.






CY21(55)

**[0135]** In one or more embodiments,  $L_2$  in Formula 1 may be a monodentate ligand, such as  $I^-$ ,  $Br^-$ ,  $Cl^-$ , sulfide, nitrate, azide, hydroxide, cyanate, isocyanate, thiocyanate, water, acetonitrile, pyridine, ammonia, carbon monoxide,  $P(Ph)_3$ ,  $P(Ph)_2CH_3$ ,  $PPh(CH_3)_2$ , or  $P(CH_3)_3$ , but embodiments of the present disclosure are not limited thereto.



CY21(56)

**[0136]** In one or more embodiments,  $L_2$  in Formula 1 may be a bidentate ligand, such as oxalate, acetylacetonate, picolinic acid, 1,2-bis(diphenylphosphino)ethane, 1,1-bis(diphenylphosphino)methane, glycinate, or ethylenediamine, but embodiments of the present disclosure are not limited thereto.



**[0123]** In Formulae CY21(1) to CY21(56),

**[0124]**  $X_{21}$  and  $R_{21}$  are the same as described above,


**[0125]**  $R_{21a}$  to  $R_{21d}$  may each be the same as defined in connection with  $R_{21}$ , wherein each of  $R_{21}$  and  $R_{21a}$  to  $R_{21d}$  may not be hydrogen,

**[0126]** \*\* indicates a binding site to  $T_1$  in Formula 2, and


**[0127]** \* indicates a binding site to M in Formula 1.

**[0128]** In Formula 1,  $L_2$  may be a bidentate ligand each linked to M in Formula 1 via O, S, Se, N, C, P, Si, or As.


**[0137]** In one or more embodiments,  $L_2$  in Formula 1 may be a group represented by one of Formulae 3A to 3F:



3A




3B




3C

-continued



3D


[0152] a group represented by



in Formula 3C or 3D may be a group represented by one of Formulae CY12-1 to CY12-34:



3E



3F

[0138] In Formulae 3A to 3F,

[0139] Y<sub>13</sub> may be O, N, N(Z<sub>1</sub>), P(Z<sub>1</sub>)(Z<sub>2</sub>), or As(Z<sub>1</sub>)(Z<sub>2</sub>),

[0140] Y<sub>14</sub> may be O, N, N(Z<sub>3</sub>), P(Z<sub>3</sub>)(Z<sub>4</sub>), or As(Z<sub>3</sub>)(Z<sub>4</sub>),

[0141] T<sub>11</sub> may be a single bond, a double bond, \*—C(Z<sub>11</sub>)(Z<sub>12</sub>)—\*, \*—C(Z<sub>11</sub>)=C(Z<sub>12</sub>)—\*, \*—C(Z<sub>11</sub>)=\*, \*—C(Z<sub>11</sub>)=\*, \*—C(Z<sub>11</sub>)—C(Z<sub>12</sub>)=C(Z<sub>13</sub>)—\*, \*—C(Z<sub>11</sub>)=C(Z<sub>12</sub>)—C(Z<sub>13</sub>)—\*, \*—N(Z<sub>11</sub>)—\*, or a C<sub>5</sub>-C<sub>30</sub> carbocyclic group unsubstituted or substituted with at least one Z<sub>11</sub>,

[0142] a<sub>11</sub> may be an integer from 1 to 10, when a<sub>11</sub> is 2 or more, two or more groups T<sub>11</sub> are identical to or different from each other,

[0143] Y<sub>11</sub> and Y<sub>12</sub> may each independently be C or N,

[0144] T<sub>21</sub> may be a single bond, a double bond, O, S, C(Z<sub>11</sub>)(Z<sub>12</sub>), Si(Z<sub>11</sub>)(Z<sub>12</sub>), or N(Z<sub>11</sub>),

[0145] ring CY<sub>11</sub> and ring CY<sub>12</sub> may each independently be a C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a C<sub>1</sub>-C<sub>30</sub> heterocyclic group,


[0146] A<sub>1</sub> may be P or As,

[0147] Z<sub>1</sub> to Z<sub>4</sub> and Z<sub>11</sub> to Z<sub>13</sub> may each be the same as defined in connection with R<sub>21</sub>,


[0148] d<sub>1</sub> and d<sub>2</sub> may each independently be an integer from 0 to 10, and

[0149] \* and \*' each indicate a binding site to M in Formula 1.


[0150] In Formulae 3A to 3F, the C<sub>5</sub>-C<sub>30</sub> carbocyclic group and the C<sub>1</sub>-C<sub>30</sub> heterocyclic group may each be the same as defined in connection with ring CY<sub>21</sub>.




[0151] For example, a group represented by in Formula 3D may be a group represented by one of Formulae CY11-1 to CY11-34, and/or




CY11-1




CT11-2




CY11-3




CY11-4



CY11-5









CY11-6




CY11-7

-continued




-continued


CY11-8




CY11-9




CY11-10




CY11-11



CY11-12



CY11-13



CY11-14

CY11-15







CY11-16

CY11-17

CY11-18


CY11-19

-continued




-continued

CY11-20




CY11-26

CY11-21




CY11-27

CY11-22




CY11-28

CY11-23




CY11-29

CY11-24










CY11-30

CY11-25




CY11-31

-continued




-continued


CY11-32




CY11-33




CY11-34




CY12-1




CY12-2



CY12-3



CY12-4



CY12-5

CY12-6

CY12-7






CY12-8

CY12-9

CY12-10


CY12-11

-continued




-continued


CY12-12




CY12-13





CY12-14



CY12-15



CY12-16



CY12-17

CY12-18


CY12-19

CY12-20


CY12-21

CY12-22


-continued




CY12-23




CY12-29




CY12-24




CY12-30




CY12-25




CY12-31




CY12-26




CY12-32




CY12-27



CY12-33



CY12-28



CY12-34

[0153] In Formulae CY11-1 to CY11-34 and CY12-1 to CY12-34,

[0154] X<sub>31</sub> may be O, S, N(Z<sub>11</sub>), C(Z<sub>11</sub>)(Z<sub>12</sub>), or Si(Z<sub>11</sub>)(Z<sub>12</sub>),

[0155] X<sub>41</sub> may be O, S, N(Z<sub>21</sub>), C(Z<sub>21</sub>)(Z<sub>22</sub>), or Si(Z<sub>21</sub>)(Z<sub>22</sub>),

[0156] Y<sub>11</sub>, Y<sub>12</sub>, Z<sub>1</sub>, and Z<sub>2</sub> are the same as described above,

[0157] Z<sub>11</sub> to Z<sub>18</sub> and Z<sub>21</sub> to Z<sub>28</sub> may each be the same as defined in connection with R<sub>21</sub>,

[0158] d12 and d22 may each independently be an integer from 0 to 2,

[0159] d13 and d23 may each independently be an integer from 0 to 3,

[0160] d14 and d24 may each independently be an integer from 0 to 4,

[0161] d15 and d25 may each independently be an integer from 0 to 5,


[0162] d16 and d26 may each independently be an integer from 0 to 6, and

[0163] in Formulae CY11-1 to CY11-34 and CY12-1 to CY12-34, \* and \*' each indicate a binding site to M in Formula 1, and \*'' indicates a binding site to a neighboring atom in Formula 3C or to T<sub>21</sub> in Formula 3D.


[0164] In an embodiment, L<sub>2</sub> in Formula 1 may be a group represented by one of Formulae 3-1(1) to 3-1(66) and 3-1(301) to 3-1(309), but embodiments of the present disclosure are not limited thereto:

-continued


3-1(4)




3-1(5)




3-1(6)





3-1(7)




3-1(8)




3-1(9)



3-1(1)









3-1(2)




3-1(3)

-continued




-continued

3-1(10)




3-1(16)

3-1(11)




3-1(17)

3-1(12)




3-1(18)

3-1(13)




3-1(19)

3-1(14)




3-1(20)

3-1(15)




3-1(21)

-continued




3-1(22)


-continued




3-1(27)




3-1(23)




3-1(28)




3-1(24)




3-1(29)




3-1(25)



3-1(30)




3-1(26)




3-1(31)


-continued




3-1(32)




3-1(37)




3-1(33)




3-1(38)




3-1(34)




3-1(39)




3-1(35)



3-1(40)




3-1(36)




3-1(41)


-continued




3-1(42)




3-1(43)



3-1(44)




3-1(45)




3-1(46)


-continued




3-1(47)




3-1(48)



3-1(49)




3-1(50)




3-1(51)

-continued




3-1(52)


-continued




3-1(56)




3-1(53)




3-1(57)




3-1(54)



3-1(58)




3-1(55)




3-1(59)


-continued




3-1(60)



3-1(61)




3-1(62)




3-1(63)


-continued




3-1(64)




3-1(65)




3-1(301)



3-1(302)




3-1(303)




3-1(304)


-continued




3-1(305)




3-1(306)



3-1(307)



3-1(308)



3-1(309)

**[0165]** In Formulae 3-1 (1) to 3-1(66) and 3-1(301) to 3-1(309),

**[0166]**  $X_{41}$  may be O, S, N( $Z_{21}$ ), C( $Z_{21}$ )( $Z_{22}$ ), or Si( $Z_{21}$ )( $Z_{22}$ ),

**[0167]**  $Z_1$  to  $Z_4$ ,  $Z_{1a}$ ,  $Z_{1b}$ ,  $Z_{1c}$ ,  $Z_{1d}$ ,  $Z_{2a}$ ,  $Z_{2b}$ ,  $Z_{2c}$ ,  $Z_{2d}$ , and  $Z_{11}$  to  $Z_{14}$  may each be the same as defined in connection with  $R_{21}$ ,

**[0168]**  $d_{14}$  may be an integer from 0 to 4,

**[0169]**  $d_{26}$  may be an integer from 0 to 6,

**[0170]** \* and \*' each indicate a binding site to M in Formula 1.

**[0171]** In an embodiment,  $L_2$  in Formula 1 may be a group represented by Formula 3-1(301).

**[0172]** In an embodiment, at least one of  $Z_{11}$  and  $Z_{13}$  in Formula 3-1(301) may not be a methyl group.

**[0173]** In an embodiment,  $Z_{11}$  and  $Z_{13}$  in Formula 3-1(301) may not be a methyl group, simultaneously.

**[0174]** In an embodiment, at least one of  $Z_{11}$  and  $Z_{13}$  in Formula 3-1(301) may each independently be a substituted or unsubstituted  $C_3$ - $C_{60}$  alkyl group, or a substituted or unsubstituted  $C_3$ - $C_{10}$  cycloalkyl group.

**[0175]** In an embodiment,  $Z_{11}$  and  $Z_{13}$  in Formula 3-1(301) may each independently be a substituted or unsubstituted  $C_3$ - $C_{60}$  alkyl group, or a substituted or unsubstituted  $C_3$ - $C_{10}$  cycloalkyl group.

**[0176]** In an embodiment, at least one of  $Z_{11}$  and  $Z_{13}$  in Formula 3-1(301) may each independently be a substituted or unsubstituted  $C_3$ - $C_{10}$  cycloalkyl group.

**[0177]** In an embodiment,  $Z_{11}$  and  $Z_{13}$  in Formula 3-1(301) may each independently be a substituted or unsubstituted  $C_3$ - $C_{10}$  cycloalkyl group.


**[0178]** In an embodiment,  $Z_{11}$  and  $Z_{13}$  in Formula 3-1(301) may each independently be:

**[0179]** a  $C_3$ - $C_{20}$  alkyl group;

**[0180]** a  $C_3$ - $C_{20}$  alkyl group substituted with deuterium, a  $C_1$ - $C_{10}$  alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantyl group, a norbornyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, a ( $C_1$ - $C_{20}$  alkyl)cyclopentyl group, a ( $C_1$ - $C_{20}$  alkyl)cyclohexyl group, a ( $C_1$ - $C_{20}$  alkyl)cycloheptyl group, a ( $C_1$ - $C_{20}$  alkyl)cyclooctyl group, a ( $C_1$ - $C_{20}$  alkyl)adamantanyl group, a ( $C_1$ - $C_{20}$  alkyl)norbornanyl group, a ( $C_1$ - $C_{20}$  alkyl)norbornenyl group, a ( $C_1$ - $C_{20}$  alkyl)cyclopentenyl group, a ( $C_1$ - $C_{20}$  alkyl)cyclohexenyl group, a ( $C_1$ - $C_{20}$  alkyl)cycloheptenyl group, a ( $C_1$ - $C_{20}$  alkyl)bicyclo[1.1.1]pentyl group, a ( $C_1$ - $C_{20}$  alkyl)bicyclo[2.1.1]hexyl group, a ( $C_1$ - $C_{20}$  alkyl)bicyclo[2.2.1]heptyl group, a ( $C_1$ - $C_{20}$  alkyl)bicyclo[2.2.2]octyl group, or any combination thereof; or

**[0181]** a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantyl group, a norbornyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, each unsubstituted or substituted with deuterium, a  $C_1$ - $C_{20}$  alkyl group, a deuterium-containing  $C_2$ - $C_{20}$  alkyl group (for example,  $*-C(CD_3)_3$ ), a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantyl group, a norbornyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, a ( $C_1$ - $C_{20}$  alkyl)cyclopentyl group, a ( $C_1$ - $C_{20}$  alkyl)cyclohexyl group, a ( $C_1$ - $C_{20}$  alkyl)cycloheptyl group, a ( $C_1$ - $C_{20}$  alkyl)cyclooctyl group, a ( $C_1$ - $C_{20}$  alkyl)adamantanyl group, a ( $C_1$ - $C_{20}$  alkyl)norbornanyl group, a ( $C_1$ - $C_{20}$  alkyl)norbornenyl group, a ( $C_1$ - $C_{20}$  alkyl)cyclopentenyl group, a ( $C_1$ - $C_{20}$  alkyl)cyclohexenyl group, a ( $C_1$ - $C_{20}$  alkyl)cycloheptenyl group, a ( $C_1$ - $C_{20}$  alkyl)bicyclo[1.1.1]pentyl group, a ( $C_1$ - $C_{20}$  alkyl)bicyclo[2.1.1]hexyl group, a ( $C_1$ - $C_{20}$  alkyl)bicyclo[2.2.1]heptyl group, a ( $C_1$ - $C_{20}$  alkyl)bicyclo[2.2.2]octyl group, or any combination thereof.

**[0182]** In an embodiment,  $L_2$  in Formula 1 may be a group represented by Formula 3-1-1, but embodiments of the present disclosure are not limited thereto:



3-1-1

**[0183]** In Formula 3-1-1,

**[0184]**  $Z_{12}$  may be the same as defined in connection with  $R_{21}$ ,

**[0185]**  $A_2$  and  $A_5$  may each independently be hydrogen, deuterium, a substituted or unsubstituted  $C_1$ - $C_{60}$  alkyl group, a substituted or unsubstituted  $C_2$ - $C_{60}$  alkenyl group, a substituted or unsubstituted  $C_2$ - $C_{60}$  alkynyl group, a substituted or unsubstituted  $C_1$ - $C_{60}$  alkoxy group, a substituted or unsubstituted  $C_3$ - $C_{10}$  cycloalkyl group, a substituted or unsubstituted  $C_1$ - $C_{10}$  heterocycloalkyl group, a substituted or unsubstituted  $C_3$ - $C_{10}$  cycloalkenyl group, a substituted or unsubstituted  $C_1$ - $C_{10}$  heterocycloalkenyl group, a substituted or unsubstituted  $C_6$ - $C_{60}$  aryl group, a substituted or unsubstituted  $C_6$ - $C_{60}$  aryloxy group, a substituted or unsubstituted  $C_6$ - $C_{60}$  arylthio group, a substituted or unsubstituted  $C_7$ - $C_{60}$  arylalkyl group, a substituted or unsubstituted  $C_1$ - $C_{60}$  heteroaryl group, a substituted or unsubstituted  $C_1$ - $C_{60}$  heteroaryloxy group, a substituted or unsubstituted  $C_1$ - $C_{60}$  heteroarylthio group, a substituted or unsubstituted  $C_2$ - $C_{60}$  heteroarylalkyl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, or a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group,

**[0186]**  $A_1$ ,  $A_3$ ,  $A_4$ , and  $A_6$  may each independently be a substituted or unsubstituted  $C_1$ - $C_{60}$  alkyl group, a substituted or unsubstituted  $C_2$ - $C_{60}$  alkenyl group, a substituted or unsubstituted  $C_2$ - $C_{60}$  alkynyl group, a substituted or unsubstituted  $C_1$ - $C_{60}$  alkoxy group, a substituted or unsubstituted  $C_3$ - $C_{10}$  cycloalkyl group, a substituted or unsubstituted  $C_1$ - $C_{10}$  heterocycloalkyl group, a substituted or unsubstituted  $C_3$ - $C_{10}$  cycloalkenyl group, a substituted or unsubstituted  $C_1$ - $C_{10}$  heterocycloalkenyl group, a substituted or unsubstituted  $C_6$ - $C_{60}$  aryl group, a substituted or unsubstituted  $C_6$ - $C_{60}$  aryloxy group, a substituted or unsubstituted  $C_6$ - $C_{60}$  arylthio group, a substituted or unsubstituted  $C_7$ - $C_{60}$  arylalkyl group, a substituted or unsubstituted  $C_1$ - $C_{60}$  heteroaryl group, a substituted or unsubstituted  $C_1$ - $C_{60}$  heteroaryloxy group, a substituted or unsubstituted  $C_1$ - $C_{60}$  heteroarylthio group, a substituted or unsubstituted  $C_2$ - $C_{60}$  heteroarylalkyl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, or a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group,

**[0187]** two or more of  $A_1$  to  $A_6$  may optionally be linked to form a  $C_5$ - $C_{30}$  carbocyclic group unsubstituted or substituted with at least one  $R_{1a}$  or a  $C_1$ - $C_{30}$  heterocyclic group unsubstituted or substituted with at least one  $R_{1a}$ ,

**[0188]**  $R_{1a}$  may be the same as defined in connection with  $Z_{12}$ ,

**[0189]** a substituent(s) of the substituted  $C_1$ - $C_{60}$  alkyl group, the substituted  $C_2$ - $C_{60}$  alkenyl group, the substituted  $C_2$ - $C_{60}$  alkynyl group, the substituted  $C_1$ - $C_{60}$  alkoxy group, the substituted  $C_3$ - $C_{10}$  cycloalkyl group, the substituted  $C_1$ - $C_{10}$  heterocycloalkyl group, the substituted  $C_3$ - $C_{10}$  cycloalkenyl group, the substituted  $C_1$ - $C_{60}$  heterocycloalkenyl group, the substituted  $C_6$ - $C_{60}$  aryl group, the substituted  $C_6$ - $C_{60}$  aryloxy group, the substituted  $C_6$ - $C_{60}$  arylthio group, a substituted or unsubstituted  $C_7$ - $C_{60}$  arylalkyl group, the substituted  $C_1$ - $C_{60}$  heteroaryl group, a substituted or unsubstituted  $C_1$ - $C_{60}$  heteroaryloxy group, a substituted or unsubstituted  $C_1$ - $C_{60}$  heteroarylthio group, a substituted or unsubstituted  $C_2$ - $C_{60}$  heteroarylalkyl group, the substituted

monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may be:

**[0190]** deuterium, —F, —Cl, —Br, —I, — $CD_3$ , — $CD_2H$ , — $CDH_2$ , — $CF_3$ , — $CF_2H$ , — $CFH_2$ , a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_1$ - $C_{60}$  alkyl group, a  $C_2$ - $C_{60}$  alkenyl group, a  $C_2$ - $C_{60}$  alkynyl group, or a  $C_1$ - $C_{60}$  alkoxy group;

**[0191]** a  $C_1$ - $C_{60}$  alkyl group, a  $C_2$ - $C_{60}$  alkenyl group, a  $C_2$ - $C_{60}$  alkynyl group, or a  $C_1$ - $C_{60}$  alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, — $CD_3$ , — $CD_2H$ , — $CDH_2$ , — $CF_3$ , — $CF_2H$ , — $CFH_2$ , a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_3$ - $C_{10}$  cycloalkyl group, a  $C_1$ - $C_{10}$  heterocycloalkyl group, a  $C_3$ - $C_{10}$  cycloalkenyl group, a  $C_1$ - $C_{10}$  heterocycloalkenyl group, a  $C_6$ - $C_{60}$  aryl group, a  $C_6$ - $C_{60}$  aryloxy group, a  $C_6$ - $C_{60}$  arylthio group, a  $C_7$ - $C_{60}$  arylalkyl group, a  $C_1$ - $C_{60}$  heteroaryl group, a  $C_1$ - $C_{60}$  heteroaryloxy group, a  $C_1$ - $C_{60}$  heteroarylthio group, a  $C_2$ - $C_{60}$  heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N( $Q_{11}$ )( $Q_{12}$ ), —Si( $Q_{13}$ )( $Q_{14}$ )( $Q_{15}$ ), —Ge( $Q_{13}$ )( $Q_{14}$ )( $Q_{15}$ ), —B( $Q_{16}$ )( $Q_{17}$ ), —P(=O)( $Q_{18}$ )( $Q_{19}$ ), —P( $Q_{18}$ )( $Q_{19}$ ), or any combination thereof;

**[0192]** a  $C_3$ - $C_{10}$  cycloalkyl group, a  $C_1$ - $C_{10}$  heterocycloalkyl group, a  $C_3$ - $C_{10}$  cycloalkenyl group, a  $C_1$ - $C_{10}$  heterocycloalkenyl group, a  $C_6$ - $C_{60}$  aryl group, a  $C_6$ - $C_{60}$  aryloxy group, a  $C_6$ - $C_{60}$  arylthio group, a  $C_7$ - $C_{60}$  arylalkyl group, a  $C_1$ - $C_{60}$  heteroaryl group, a  $C_1$ - $C_{60}$  heteroaryloxy group, a  $C_1$ - $C_{60}$  heteroarylthio group, a  $C_2$ - $C_{60}$  heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, or a monovalent non-aromatic condensed heteropolycyclic group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, — $CD_3$ , — $CD_2H$ , — $CDH_2$ , — $CF_3$ , — $CF_2H$ , — $CFH_2$ , a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_1$ - $C_{60}$  alkyl group, a  $C_2$ - $C_{60}$  alkenyl group, a  $C_2$ - $C_{60}$  alkynyl group, a  $C_1$ - $C_{60}$  alkoxy group, a  $C_3$ - $C_{10}$  cycloalkyl group, a  $C_1$ - $C_{10}$  heterocycloalkyl group, a  $C_3$ - $C_{10}$  cycloalkenyl group, a  $C_1$ - $C_{10}$  heterocycloalkenyl group, a  $C_6$ - $C_{60}$  aryl group, a  $C_6$ - $C_{60}$  aryloxy group, a  $C_6$ - $C_{60}$  arylthio group, a  $C_7$ - $C_{60}$  arylalkyl group, a  $C_1$ - $C_{60}$  heteroaryl group, a  $C_1$ - $C_{60}$  heteroaryloxy group, a  $C_1$ - $C_{60}$  heteroarylthio group, a  $C_2$ - $C_{60}$  heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N( $Q_{21}$ )( $Q_{22}$ ), —Si( $Q_{23}$ )( $Q_{24}$ )( $Q_{25}$ ), —Ge( $Q_{23}$ )( $Q_{24}$ )( $Q_{25}$ ), —B( $Q_{26}$ )( $Q_{27}$ ), —P(=O)( $Q_{28}$ )( $Q_{29}$ ), —P( $Q_{28}$ )( $Q_{29}$ ), or any combination thereof;

**[0193]** —N( $Q_{31}$ )( $Q_{32}$ ), —Si( $Q_{33}$ )( $Q_{34}$ )( $Q_{35}$ ), —Ge( $Q_{33}$ )( $Q_{34}$ )( $Q_{35}$ ), —B( $Q_{36}$ )( $Q_{37}$ ), —P(=O)( $Q_{38}$ )( $Q_{39}$ ), or —P( $Q_{38}$ )( $Q_{39}$ ); or

**[0194]** any combination thereof.

**[0195]** In an exemplary embodiment,  $Q_{11}$  to  $Q_{19}$ ,  $Q_{21}$  to  $Q_{29}$ , and  $Q_{31}$  to  $Q_{39}$  may each independently be hydrogen;

deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; an amidino group; a hydrazine group; a hydrazone group; a carboxylic acid group or a salt thereof; a sulfonic acid group or a salt thereof; a phosphoric acid group or a salt thereof; a C<sub>1</sub>-C<sub>60</sub> alkyl group unsubstituted or substituted with deuterium, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, or any combination thereof; a C<sub>2</sub>-C<sub>60</sub> alkenyl group; a C<sub>2</sub>-C<sub>60</sub> alkylnyl group; a C<sub>1</sub>-C<sub>60</sub> alkoxy group; a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group; a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group; a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group; a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group; a C<sub>6</sub>-C<sub>60</sub> aryl group unsubstituted or substituted with deuterium, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, or any combination thereof; a C<sub>6</sub>-C<sub>60</sub> aryloxy group; a C<sub>6</sub>-C<sub>60</sub> arylthio group; a C<sub>7</sub>-C<sub>60</sub> arylalkyl group; a C<sub>1</sub>-C<sub>60</sub> heteroaryl group; a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group; a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group; a C<sub>7</sub>-C<sub>60</sub> arylalkyl group; a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group; a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group; a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group; a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group; a monovalent non-aromatic condensed polycyclic group; or a monovalent non-aromatic condensed heteropolycyclic group.

**[0196]** In an embodiment, A<sub>1</sub> to A<sub>6</sub> and Z<sub>12</sub> in Formula 3-1-1 may each independently be:

**[0197]** hydrogen, deuterium, a cyano group, C<sub>1</sub>-C<sub>20</sub> alkyl group, or a C<sub>1</sub>-C<sub>20</sub> alkoxy group;

**[0198]** a C<sub>1</sub>-C<sub>20</sub> alkyl group and a C<sub>1</sub>-C<sub>20</sub> alkoxy group, each substituted with deuterium, —F, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a cyano group, a C<sub>1</sub>-C<sub>10</sub> alkyl group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantyl group, a norbornyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cyclopentyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cyclohexyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cycloheptyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cyclooctyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)adamantanyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)norbornanyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)norbornenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cyclopentenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cyclohexenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cycloheptenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)bicyclo[1.1.1]pentyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)bicyclo[2.1.1]hexyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)bicyclo[2.2.1]heptyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)bicyclo[2.2.2]octyl group, a phenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)phenyl group, a biphenyl group, a terphenyl group, or any combination thereof; or

**[0199]** a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantyl group, a norbornyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, a phenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)phenyl group, a biphenyl group, or a terphenyl group, each unsubstituted or substituted with deuterium, —F, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a cyano group, a C<sub>1</sub>-C<sub>20</sub> alkyl group, a deuterium-containing C<sub>2</sub>-C<sub>20</sub> alkyl group (for example, \*—C(CD<sub>3</sub>)<sub>3</sub>), a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantyl group, a norbornyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cyclopentyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)

cyclohexyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cycloheptyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cyclooctyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)adamantanyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)norbornanyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)norbornenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cyclopentenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cyclohexenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cycloheptenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)bicyclo[1.1.1]pentyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)bicyclo[2.1.1]hexyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)bicyclo[2.2.1]heptyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)bicyclo[2.2.2]octyl group, a phenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)phenyl group, a biphenyl group, a terphenyl group, or any combination thereof;

**[0200]** wherein each of A<sub>1</sub>, A<sub>3</sub>, A<sub>4</sub>, and A<sub>6</sub> may not be hydrogen nor deuterium.

**[0201]** In an embodiment, A<sub>1</sub> to A<sub>6</sub> and Z<sub>12</sub> in Formula 3-1-1 may each independently be:

**[0202]** hydrogen or deuterium;

**[0203]** a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, or a sec-isopentyl group, each unsubstituted or substituted with deuterium, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, a sec-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neopentyl group, an isopentyl group, a sec-pentyl group, a 3-pentyl group, a sec-isopentyl group, or any combination thereof; or

**[0204]** a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantyl group, a norbornyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, a phenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)phenyl group, a biphenyl group, or a terphenyl group, each unsubstituted or substituted with deuterium, —F, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a cyano group, a C<sub>1</sub>-C<sub>20</sub> alkyl group, a deuterium-containing C<sub>2</sub>-C<sub>20</sub> alkyl group (for example, \*—C(CD<sub>3</sub>)<sub>3</sub>), a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantyl group, a norbornyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cyclopentyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cyclohexyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cycloheptyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cyclooctyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)adamantanyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)norbornanyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)norbornenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cyclopentenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cyclohexenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)cycloheptenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)bicyclo[1.1.1]pentyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)bicyclo[2.1.1]hexyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)bicyclo[2.2.1]heptyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)bicyclo[2.2.2]octyl group, a phenyl group, a (C<sub>1</sub>-C<sub>20</sub> alkyl)phenyl group, a biphenyl group, a terphenyl group, or any combination thereof;

**[0205]** wherein each of A<sub>1</sub>, A<sub>3</sub>, A<sub>4</sub>, and A<sub>6</sub> may not be hydrogen nor deuterium.

**[0206]** In one or more embodiments, all of A<sub>i</sub> to A<sub>6</sub> in Formula 3-1-1 may not be hydrogen.

**[0207]** In one or more embodiments, all of A<sub>i</sub> to A<sub>6</sub> in Formula 3-1-1 may not be hydrogen nor deuterium.

[0208] In one or more embodiments,  $L_1$  in Formula 1 may include at least one deuterium.

[0209] In one or more embodiments,  $L_1$  in Formula 1 may include at least one fluoro group ( $-F$ ).

[0210] In one or more embodiments, in Formula 2,  $a_1$  may not be 0 (zero) and at least one  $R_1$  in number of  $a_1$  may include at least one deuterium.

[0211] In one or more embodiments, in Formula 2,  $a_1$  may not be 0 (zero) and at least one  $R_1$  in number of  $a_1$  may include at least one fluoro group ( $-F$ ).


[0212] In one or more embodiments, in Formula 2,  $a_1$  may be 0, 1 or 2.

[0213] In one or more embodiments, in Formula 2, a condensed cyclic group in which a ring  $CY_{11}$  and a ring  $CY_{12}$  are condensed with each other may have two, three or four rings which are condensed with each other.





[0214] The organometallic compound represented by Formula 1 may emit visible light having a maximum emission wavelength of, for example, about 450 nm or more and about 700 nm or less. In an exemplary device, the visible light may be a red light.

[0215] The terms “an azaindole group, an azabenzoborole group, an azabenzophosphole group, an azaindene group, an azabenzosilole group, an azabenzogermole group, an azabenzothiophene group, an azabenzoselenophene group, an azabenzofuran group, an azacarbazole group, an azadibenzoborole group, an azadibenzophosphole group, an azafluorene group, an azadibenzosilole group, an azadibenzogermole group, an azadibenzothiophene group, an azadibenzoselenophene group, an azadibenzofuran group, an azadibenzothiophene 5-oxide group, an aza-9H-fluorene-9-one group, and an azadibenzothiophene 5,5-dioxide group” as used herein each refer to a hetero-ring having the same backbone as “an indole group, a benzoborole group, a benzophosphole group, an indene group, a benzosilole group, a benzogermole group, a benzothiophene group, a benzoselenophene group, a benzofuran group, a carbazole group, a dibenzoborole group, a dibenzophosphole group, a fluorene group, a dibenzosilole group, a dibenzogermole group, a dibenzothiophene group, a dibenzoselenophene group, a dibenzofuran group, a dibenzothiophene 5-oxide group, a 9H-fluorene-9-one group, and a dibenzothiophene 5,5-dioxide group”, in which at least one carbon atom constituting a ring of the aforementioned groups is replaced with nitrogen atom.

[0216] In an embodiment, the organometallic compound may be one of Compounds 1 to 366, but embodiments of the present disclosure are not limited thereto:




-continued




-continued


-continued




6




10




7




11




8



12




9




13

-continued


14




15



16




17




-continued


18






19







20



-continued











-continued




-continued

-continued




-continued




36


-continued




40




37




41




38



42




39




43


-continued




44



45




46




47


-continued




48



49




50








51


-continued



-continued




-continued




58


-continued




61




59



62









60







63

-continued

-continued




-continued




-continued

70




74

71




76

72




76

73




77




78


-continued




79




80



81




82




83


-continued




84




85



86




87




88


-continued




89




90



91




92




93


-continued




94




95



96




97




98

-continued




99

-continued




103


100




104




101




105



102











106











-continued

-continued







-continued





-continued




-continued










-continued



-continued










-continued







-continued





-continued



-continued




-continued




-continued


154




155



156




157




-continued


158




159




160



161




-continued




162


-continued




166




163




167




164



168







165







169





-continued







-continued




-continued



-continued




-continued




186

-continued




187


190




188




191




189



192







189







193





-continued







-continued




-continued




-continued




-continued








-continued







-continued






-continued




-continued









-continued







-continued






-continued







-continued






-continued






-continued







-continued



-continued




-continued




-continued

-continued


259




260




261




262




263







264







265



-continued











-continued











-continued

-continued











-continued

-continued







-continued



-continued




-continued








-continued




-continued




-continued




-continued




311




314




312



315




313




316

-continued




317


-continued




320




318



321




319




322


-continued




-continued




324




327



325









328






-continued





-continued




-continued



-continued




-continued




342


-continued




345




343



346




344




347

-continued




348


-continued




351




349




352



350




353








354


-continued



-continued




-continued




361


-continued




362




363



364



365



366

[0217] In the organometallic compound represented by Formula 1,  $L_1$  may be a ligand represented by Formula 2, and  $n_1$  which indicates the number of groups  $L_1$  may be 1, 2, or 3. In an exemplary embodiment, the organometallic compound may be a ligand linked to metal M, and essentially includes at least one ligand represent by Formula 2.

[0218] In Formula 2, ring  $CY_{11}$  and ring  $CY_{12}$  may be condensed with each other. In this regard, in the ligand represented by Formula 2, a conjugate length of a moiety (a phore) concerning a lowest unoccupied molecular orbital (LUMO) may increase, thereby increasing the electron transition. Accordingly, the organometallic compound including the ligand represented by Formula 2 may have increased radiative decay, and therefore, an electronic device, for example, an organic light-emitting device, including the organometallic compound represented by Formula 1 may have improved luminescence efficiency, improved external quantum efficiency and/or improved lifetime.

[0219] In addition,  $T_1$  in Formula 2 may be  $*-N(R_2)-*^1$ ,  $*-B(R_2)-*^1$ ,  $*-P(R_2)-*^1$ ,  $*-C(R_2)(R_3)-*^1$ ,  $*-Si(R_2)(R_3)-*^1$ ,  $*-Ge(R_2)(R_3)-*^1$ ,  $*-S-*^1$ ,  $*-Se-*^1$ ,  $*-O-*^1$ ,  $*-C(=O)-*^1$ ,  $*-S(=O)-*^1$ ,  $*-S(=O)_2-*^1$ ,  $*-C(R_2)=*^1$ ,  $*-C(R_2)-*^1$ ,  $*-C(R_2)-C(R_3)-*^1$ ,  $*-C(=S)-*^1$ , or  $*-C\equiv C-*^1$ . That is,  $T_1$  in Formula 2 may not be a single bond. In this regard, a non-covalent electron included in  $T_1$  in the organometallic compound represented by Formula 1 may increase a spin-orbital coupling effect between the metal and the ligand, and therefore,

an electronic device, for example, an organic light-emitting device, including the organometallic compound represented by Formula 1 may have improved luminescence efficiency, improved external quantum efficiency and/or improved lifetime.

[0220] Furthermore, metal M in Formula 1 may be Ir, Os, Ti, Hf, Eu, Rh, or Ru. Although not limited to a particular theory, the organometallic compound represented by Formula 1 and having metal M may have, for example, a large spin-orbital coupling value relative to Pt. In this regard, the interphase transition between a triplet state and a singlet triplet may increase, thereby having improved quantum luminescence efficiency and relatively short decay time. Therefore, an electronic device, for example, an organic light-emitting device, including the organometallic compound represented by Formula 1 may have improved lifespan.

[0221] A highest occupied molecular orbital (HOMO) energy level, a lowest unoccupied molecular orbital (LUMO) energy level, a band gap, a singlet (S<sub>1</sub>) energy level and a triplet (T<sub>1</sub>) energy level of some of the organometallic compound represented by Formula 1 were evaluated by using a Gaussian 09 program accompanied with optimization of molecular structure according to B3LYP-based density functional theory (DFT). Results thereof are shown in Table 1 below.

TABLE 1

Compound No.	HOMO (eV)	LUMO (eV)	Band gap (eV)	S <sub>1</sub> (eV)	T <sub>1</sub> (eV)
2	-4.69	-1.59	3.10	2.37	2.46
32	-4.71	-1.94	2.77	2.14	2.10
33	-4.70	-1.94	2.76	2.14	2.10
47	-4.67	-2.20	2.47	2.06	2.03
69	-4.51	-2.01	2.50	1.93	1.90

[0222] Referring to Table 1, it is confirmed that the organometallic compound represented by Formula 1 has such electric characteristics that are suitable for use in an electric device, for example, for use as a dopant for an organic light-emitting device.

[0223] Synthesis methods of the organometallic compound represented by Formula 1 may be recognizable by one of ordinary skill in the art by referring to Synthesis Examples provided below.

[0224] The organometallic compound represented by Formula 1 is suitable for use in an organic layer of an organic light-emitting device, for example, for use as a dopant in an emission layer of the organic layer. Thus, another aspect provides an organic light-emitting device that includes: a first electrode; a second electrode; and an organic layer that is disposed between the first electrode and the second electrode and includes an organic layer including an emission layer and at least one of the organometallic compounds represented by Formula 1.

[0225] The organic light-emitting device may have, due to the inclusion of an organic layer including the organometallic compound represented by Formula 1, an improved driving voltage, an improved external quantum efficiency, an improved long lifespan, and an improved low roll-off ratio.

[0226] The organometallic compound represented by Formula 1 may be used between a pair of electrodes of an organic light-emitting device. For example, the organometallic compound represented by Formula 1 may be included

in the emission layer. In this regard, the organometallic compound may act as a dopant, and the emission layer may further include a host (that is, an amount of the organometallic compound represented by Formula 1 is smaller than an amount of the host). The emission layer may emit visible light having a maximum emission wavelength of, for example, about 450 nanometers (nm) or more and about 700 nm or less.

[0227] The expression “(an organic layer) includes at least one organometallic compound” as used herein may include an embodiment in which “(an organic layer) includes identical organometallic compounds represented by Formula 1” and an embodiment in which “(an organic layer) includes two or more different organometallic compounds represented by Formula 1”.

[0228] In an exemplary embodiment, the organic layer may include, as the organometallic compound, only Compound 1. In this regard, Compound 1 may be included only in the emission layer of the organic light-emitting device. In one or more embodiments, the organic layer may include, as the organometallic compound, Compound 1 and Compound 2. In this regard, Compound 1 and Compound 2 may be included in an identical layer (for example, Compound 1 and Compound 2 all may exist in an emission layer).

[0229] The first electrode may be an anode, which is a hole injection electrode, and the second electrode may be a cathode, which is an electron injection electrode; or the first electrode may be a cathode, which is an electron injection electrode, and the second electrode may be an anode, which is a hole injection electrode.

[0230] In an embodiment, in the organic light-emitting device, the first electrode may be an anode, the second electrode may be a cathode, and the organic layer may further include a hole transport region between the first electrode and the emission layer and an electron transport region between the emission layer and the second electrode, wherein the hole transport region may include a hole injection layer, a hole transport layer, an electron blocking layer, or a buffer layer, or any combination thereof, and the electron transport region may include a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

[0231] The term “organic layer” used herein refers to a single layer and/or a plurality of layers disposed between the first electrode and the second electrode of an organic light-emitting device. The “organic layer” may include, in addition to an organic compound, an organometallic complex including metal.

[0232] The FIGURE is a schematic cross-sectional view of an organic light-emitting device **10** according to an embodiment. Hereinafter, the structure of an organic light-emitting device according to an embodiment and a method of manufacturing an organic light-emitting device according to an embodiment will be described in connection with the FIGURE. The organic light-emitting device **10** includes a first electrode **11**, an organic layer **15**, and a second electrode **19**, which are sequentially stacked.

[0233] A substrate may be additionally disposed under the first electrode **11** or above the second electrode **19**. For use as the substrate, any substrate that is used in general organic light-emitting devices may be used, and the substrate may be a glass substrate or a transparent plastic substrate, each

having excellent mechanical strength, thermal stability, transparency, surface smoothness, ease of handling, and water resistance.

[0234] The first electrode **11** may be formed by depositing or sputtering a material for forming the first electrode **11** on the substrate. The first electrode **11** may be an anode. The material for forming the first electrode **11** may be selected from materials with a high work function to facilitate hole injection. The first electrode **11** may be a reflective electrode, a semi-transmissive electrode, or a transmissive electrode. The material for forming the first electrode may be, for example, indium tin oxide (ITO), indium zinc oxide (IZO), tin oxide (SnO<sub>2</sub>), and zinc oxide (ZnO). In one or more embodiments, the material for forming the first electrode **11** may be metal, such as magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), or magnesium-silver (Mg—Ag).

[0235] The first electrode **11** may have a single-layered structure or a multi-layered structure including two or more layers. In an embodiment, the first electrode **11** may have a three-layered structure of ITO/Ag/ITO, but the structure of the first electrode **110** is not limited thereto.

[0236] The organic layer **15** is disposed on the first electrode **11**.

[0237] The organic layer **15** may include a hole transport region, an emission layer, and an electron transport region.

[0238] The hole transport region may be disposed between the first electrode **11** and the emission layer.

[0239] The hole transport region may include a hole injection layer, a hole transport layer, an electron blocking layer, a buffer layer, or any combination thereof.

[0240] The hole transport region may include only either a hole injection layer or a hole transport layer. In one or more embodiments, the hole transport region may have a hole injection layer/hole transport layer structure or a hole injection layer/hole transport layer/electron blocking layer structure, which are sequentially stacked in this stated order from the first electrode **11**.

[0241] When the hole transport region includes a hole injection layer, the hole injection layer may be formed on the first electrode **11** by using one or more suitable methods, for example, vacuum deposition, spin coating, casting, and/or Langmuir-Blodgett (LB) deposition.



[0242] When a hole injection layer is formed by vacuum deposition, the deposition conditions may vary according to a material that is used to form the hole injection layer, and the structure and thermal characteristics of the hole injection layer. In an exemplary embodiment, the deposition conditions may include a deposition temperature of about 100 degree Celsius (° C.) to about 500° C., a vacuum pressure of about 10<sup>-8</sup> torr to about 10<sup>-3</sup> torr, and a deposition rate of about 0.01 angstrom per seconds (Å/sec) to about 100 Å/sec. However, the deposition conditions are not limited thereto.

[0243] When the hole injection layer is formed using spin coating, coating conditions may vary according to the material used to form the hole injection layer, and the structure and thermal properties of the hole injection layer. For example, a coating speed may be from about 2,000 revolutions per minute (rpm) to about 5,000 rpm, and a tempera-


ture at which a heat treatment is performed to remove a solvent after coating may be from about 80° C. to about 200° C. However, the coating conditions are not limited thereto.

[0244] Conditions for forming a hole transport layer and an electron blocking layer may be understood by referring to conditions for forming the hole injection layer.


[0245] The hole transport region may include m-MT-DATA, TDATA, 2-TNATA, NPB, β-NPB, TPD, Spiro-TPD, Spiro-NPB, methylated-NPB, TAPC, HMTPD, 4,4',4''-tris (N-carbazolyl)triphenylamine (TCTA), polyaniline/dodecylbenzenesulfonic acid (PANI/DBSA), poly(3,4-ethylenedioxythiophene)/poly(4-styrenesulfonate) (PEDOT/PSS), polyaniline/camphor sulfonic acid (PANI/CSA), polyaniline/poly(4-styrenesulfonate) (PANI/PSS), a compound represented by Formula 201 below, a compound represented by Formula 202 below, or any combination thereof:





-continued



2-TNATA




NPB


 $\beta$ -NPB

TPD


-continued




Spiro-TPD




Spiro-NPB



methylated NPB




TAPC




HMTPD

-continued

Formula 201



Formula 202



[0246]  $Ar_{101}$  and  $Ar_{102}$  in Formula 201 may each independently be a phenylene group, a pentalenylene group, an indenylene group, a naphthylene group, an azulenylene group, a heptalenylene group, an acenaphthylene group, a fluorenylene group, a phenalenylene group, a phenanthrenylene group, an anthracenylene group, a fluoranthenylene group, a triphenylenylene group, a pyrenylene group, a chrysenylenylene group, a naphthacenylene group, a pice nylenylene group, a perylenylene group, or a pentacenylene group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_1$ - $C_{60}$  alkyl group, a  $C_2$ - $C_{60}$  alkenyl group, a  $C_2$ - $C_{60}$  alkynyl group, a  $C_1$ - $C_{60}$  alkoxy group, a  $C_3$ - $C_{10}$  cycloalkyl group, a  $C_3$ - $C_{10}$  cycloalkenyl group, a  $C_1$ - $C_{10}$  heterocycloalkyl group, a  $C_1$ - $C_{10}$  heterocycloalkenyl group, a  $C_6$ - $C_{60}$  aryl group, a  $C_6$ - $C_{60}$  aryloxy group, a  $C_6$ - $C_{60}$  arylthio group, a  $C_7$ - $C_{60}$  arylalkyl group, a  $C_1$ - $C_{60}$  heteroaryl group, a  $C_1$ - $C_{60}$  heteroaryloxy group, a  $C_1$ - $C_{60}$  heteroarylthio group, a  $C_2$ - $C_{60}$  heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, or any combination thereof.

[0247] In Formula 201,  $xa$  and  $xb$  may each independently be an integer from 0 to 5, or may be 0, 1, or 2. In an exemplary embodiment,  $xa$  may be 1 and  $xb$  may be 0, but  $xa$  and  $xb$  are not limited thereto.

[0248] In Formulae 201 and 202,  $R_{101}$  to  $R_{108}$ ,  $R_{111}$  to  $R_{119}$ , and  $R_{121}$  to  $R_{124}$  may each independently be:

[0249] hydrogen, deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_1$ - $C_{10}$  alkyl group (for example, a methyl group, an ethyl group, a propyl group, a butyl group, pentyl group, a hexyl group, and the like), or a  $C_1$ - $C_{10}$  alkoxy group (for example, a methoxy group, an ethoxy group, a propoxy group, a butoxy group, a pentoxy group, and the like);


[0250] a  $C_1$ - $C_{10}$  alkyl group or a  $C_1$ - $C_{10}$  alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, or any combination thereof; or

a phenyl group, a naphthyl group, an anthracenyl group, a fluorenyl group, or a pyrenyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_1$ - $C_{10}$  alkyl group, a  $C_1$ - $C_{10}$  alkoxy group, or any combination thereof, but embodiments of the present disclosure are not limited thereto.

[0251] In Formula 201,  $R_{109}$  may be a phenyl group, a naphthyl group, an anthracenyl group, or a pyridinyl group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_1$ - $C_{20}$  alkyl group, a  $C_1$ - $C_{20}$  alkoxy group, a phenyl group, a naphthyl group, an anthracenyl group, a pyridinyl group, or any combination thereof.

[0252] In an embodiment, the compound represented by Formula 201 may be represented by Formula 201A, but embodiments of the present disclosure are not limited thereto:

Formula 201A




[0253] Detailed descriptions about  $R_{101}$ ,  $R_{111}$ ,  $R_{112}$ , and  $R_{109}$  in Formula 201A are the same as described provided herein.


[0254] For example, the compound represented by Formula 201, and the compound represented by Formula 202 may include compounds HT1 to HT20 illustrated below, but are not limited thereto:

-continued


HT3




HT1



HT4



HT2





-continued

-continued



HT5

HT7



HT6

HT8





-continued

-continued



HT11

HT9




HT12





HT10



HT13




-continued




-continued


HT18



HT19



HT20




[0255] A thickness of the hole transport region may be from about 100 angstrom (Å) to about 10,000 Å, for example, about 100 Å to about 3,000 Å. When the hole transport region includes at least one selected from a hole injection layer and a hole transport layer, a thickness of the hole injection layer may be in a range of about 100 Å to about 10,000 Å, for example, about 100 Å to about 1,000 Å, and a thickness of the hole transport layer may be in a range of about 50 Å to about 2,000 Å, for example about 100 Å to about 1,500 Å. While not wishing to be bound by theory, it is understood that when the thicknesses of the hole transport region, the hole injection layer, and the hole transport layer are within these ranges, satisfactory hole transporting characteristics may be obtained without a substantial increase in driving voltage.


[0256] The hole transport region may further include, in addition to these materials, a charge-generation material for the improvement of conductive properties. The charge-

generation material may be homogeneously or non-homogeneously dispersed in the hole transport region.

[0257] The charge-generation material may be, for example, a p-dopant. The p-dopant may be a quinone derivative, a metal oxide, a cyano group-containing compound, or any combination thereof, but embodiments of the present disclosure are not limited thereto. Non-limiting examples of the p-dopant are a quinone derivative, such as tetracyanoquinonodimethane (TCNQ) or 2,3,5,6-tetrafluoro-tetracyano-1,4-benzoquinonodimethane (F4-TCNQ); a metal oxide, such as a tungsten oxide or a molybdenum oxide; and a cyano group-containing compound, such as Compound HT-D1 below, but are not limited thereto:




HT-D1




F4-TCNQ


[0263] The host may include TPBi, TBADN, ADN (also referred to as "DNA"), CBP, CDBP, TCP, mCP, one of Compounds H50 to H52, or any combination thereof:




TPBi



TBADN



ADN



CBP







[0258] The hole transport region may include a buffer layer.

[0259] Also, the buffer layer may compensate for an optical resonance distance according to a wavelength of light emitted from the emission layer, and thus, efficiency of a formed organic light-emitting device may be improved.

[0260] Also, when the hole transport region includes an electron blocking layer, a material for the electron blocking layer may be a material for the hole transport region described above and materials for a host to be explained later. However, the material for the electron blocking layer is not limited thereto. In an exemplary embodiment, when the hole transport region includes an electron blocking layer, a material for the electron blocking layer may be mCP, which will be explained later.

[0261] Then, an emission layer may be formed on the hole transport region by vacuum deposition, spin coating, casting, LB deposition, or the like. When the emission layer is formed by vacuum deposition or spin coating, the deposition or coating conditions may be similar to those applied in forming the hole injection layer although the deposition or coating conditions may vary according to a compound that is used to form the emission layer.

[0262] The emission layer may include a host and a dopant, and the dopant may include the organometallic compound represented by Formula 1.



**[0264]** When the organic light-emitting device is a full-color organic light-emitting device, the emission layer may be patterned into a red emission layer, a green emission layer, and/or a blue emission layer. In one or more embodiments, due to a stacked structure including a red emission layer, a green emission layer, and/or a blue emission layer, the emission layer may emit white light.

**[0265]** When the emission layer includes a host and a dopant, an amount of the dopant may be in a range of about 0.01 parts by weight to about 15 parts by weight based on 100 parts by weight of the host, but embodiments of the present disclosure are not limited thereto.

**[0266]** The dopant may be an organometallic compound represented by Formula 1 described above. In an exemplary device, the dopant may be a red phosphorescent dopant.

**[0267]** A thickness of the emission layer may be in a range of about 100 Å to about 1,000 Å, for example, about 200 Å to about 600 Å. While not wishing to be bound by theory, it is understood that when the thickness of the emission layer is within this range, improved light-emission characteristics may be obtained without a substantial increase in driving voltage.


**[0268]** An electron transport region may be disposed on the emission layer.

**[0269]** The electron transport region may include a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.


**[0270]** In an exemplary embodiment, the electron transport region may have a hole blocking layer/electron transport layer/electron injection layer structure or an electron transport layer/electron injection layer structure, but the structure of the electron transport region is not limited thereto. The electron transport layer may have a single-layered structure or a multi-layered structure including two or more different materials.

**[0271]** Conditions for forming the hole blocking layer, the electron transport layer, and the electron injection layer which constitute the electron transport region may be understood by referring to the conditions for forming the hole injection layer.


**[0272]** When the electron transport region includes a hole blocking layer, the hole blocking layer may include, for example, BCP, Bphen, BA1q, or any combination thereof, but embodiments of the present disclosure are not limited thereto:




BCP



Bphen



TAZ




NTAZ

[0273] A thickness of the hole blocking layer may be from about 20 Å to about 1,000 Å, for example, about 30 Å to about 300 Å. While not wishing to be bound by theory, it is understood that when the thickness of the hole blocking layer is within these ranges, the hole blocking layer may have improved hole blocking characteristics without a substantial increase in driving voltage.




[0274] The electron transport layer may include BCP, Bphen, Alq<sub>3</sub>, BAlq, TAZ, NTAZ, or any combination thereof:

[0275] In one or more embodiments, the electron transport layer may include one of ET1 to ET25 or any combination thereof, but are not limited thereto:

ET1




ET2

Alq<sub>3</sub>


BAlq

-continued




ET3

-continued




ET6

ET4





ET7




ET8

ET5




-continued


ET9




ET10



ET11




ET12




-continued


ET13



ET14




ET15




-continued

ET16




-continued


ET19




ET17




ET20






ET18



ET21




-continued



-continued

ET22

ET25




ET23

**[0276]** A thickness of the electron transport layer may be from about 100 Å to about 1,000 Å, for example, about 150 Å to about 500 Å. While not wishing to be bound by theory, it is understood that when the thickness of the electron transport layer is within the range described above, the electron transport layer may have satisfactory electron transport characteristics without a substantial increase in driving voltage.

**[0277]** Also, the electron transport layer may further include, in addition to the materials described above, a metal-containing material.


**[0278]** The metal-containing material may include a Li complex. The Li complex may include, for example, Compound ET-D1 (LiQ) or ET-D2:

ET-D1



ET24

ET-D2



**[0279]** The electron transport region may include an electron injection layer that promotes flow of electrons from the second electrode **19** thereinto.

**[0280]** The electron injection layer may include LiF, NaCl, CsF, Li<sub>2</sub>O, BaO, or any combination thereof.

**[0281]** A thickness of the electron injection layer may be from about 1 Å to about 100 Å, for example, about 3 Å to about 90 Å. While not wishing to be bound by theory, it is understood that when a thickness of the electron injection

layer is within these ranges, satisfactory electron injection characteristics may be obtained without substantial increase in driving voltage.

[0282] The second electrode **19** is disposed on the organic layer **15**. The second electrode **19** may be a cathode. A material for forming the second electrode **19** may be a metal, an alloy, an electrically conductive compound, or any combination thereof, which have a relatively low work function. In an exemplary device, lithium (Li), magnesium (Mg), aluminum (Al), aluminum-lithium (Al—Li), calcium (Ca), magnesium-indium (Mg—In), or magnesium-silver (Mg—Ag) may be formed as the material for forming the second electrode **19**. To manufacture a top-emission type light-emitting device, a transmissive electrode formed using ITO or IZO may be used as the second electrode **19**.

[0283] Hereinbefore, the organic light-emitting device according to an embodiment has been described in connection with the FIGURE.

[0284] Another aspect of the present disclosure provides a diagnostic composition including at least one organometallic compound represented by Formula 1.

[0285] The organometallic compound represented by Formula 1 provides high luminescence efficiency. Accordingly, a diagnostic composition including the organometallic compound may have high diagnostic efficiency.

[0286] The diagnostic composition may be used in various applications including a diagnosis kit, a diagnosis reagent, a biosensor, and a biomarker.

[0287] The term “C<sub>1</sub>-C<sub>60</sub> alkyl group” as used herein refers to a linear or branched saturated aliphatic hydrocarbon monovalent group having 1 to 60 carbon atoms, and examples thereof include a methyl group, an ethyl group, a propyl group, an isobutyl group, a sec-butyl group, a tert-butyl group, a pentyl group, an isoamyl group, and a hexyl group. The term “C<sub>1</sub>-C<sub>60</sub> alkylene group” as used herein refers to a divalent group having the same structure as the C<sub>1</sub>-C<sub>60</sub> alkyl group.

[0288] The term “C<sub>1</sub>-C<sub>60</sub> alkoxy group” as used herein refers to a monovalent group represented by —OA<sub>101</sub>, (wherein A<sub>101</sub> is the C<sub>1</sub>-C<sub>60</sub> alkyl group), and examples thereof include a methoxy group, an ethoxy group, and an isopropoxy group.

[0289] The term “C<sub>2</sub>-C<sub>60</sub> alkenyl group” as used herein refers to a hydrocarbon group having at least one carbon-carbon double bond in the middle or at the terminus of the C<sub>2</sub>-C<sub>60</sub> alkyl group, and examples thereof include an ethenyl group, a propenyl group, and a butenyl group. The term “C<sub>2</sub>-C<sub>60</sub> alkenylene group” as used herein refers to a divalent group having the same structure as the C<sub>2</sub>-C<sub>60</sub> alkenyl group.

[0290] The term “C<sub>2</sub>-C<sub>60</sub> alkynyl group” as used herein refers to a hydrocarbon group having at least one carbon-carbon triple bond in the middle or at the terminus of the C<sub>2</sub>-C<sub>60</sub> alkyl group, and examples thereof include an ethynyl group, and a propynyl group. The term “C<sub>2</sub>-C<sub>60</sub> alkynylene group” as used herein refers to a divalent group having the same structure as the C<sub>2</sub>-C<sub>60</sub> alkynyl group.

[0291] The term “C<sub>3</sub>-C<sub>10</sub> cycloalkyl group” as used herein refers to a monovalent saturated hydrocarbon monocyclic group having 3 to 10 carbon atoms, and non-limiting examples thereof include a cyclopropyl group, a cyclobutyl group, a cyclopentyl group, a cyclohexyl group, and a cycloheptyl group. The term “C<sub>3</sub>-C<sub>10</sub> cycloalkylene group”

as used herein refers to a divalent group having the same structure as the C<sub>3</sub>-C<sub>10</sub> cycloalkyl group.

[0292] The term “C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group” as used herein refers to a monovalent saturated monocyclic group having at least one heteroatom selected from N, O, P, Si and S as a ring-forming atom and 1 to 10 carbon atoms, and non-limiting examples thereof include a tetrahydrofuranlyl group, and a tetrahydrothiophenyl group. The term “C<sub>1</sub>-C<sub>10</sub> heterocycloalkylene group” as used herein refers to a divalent group having the same structure as the C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group.

[0293] The term “C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group” as used herein refers to a monovalent monocyclic group that has 3 to 10 carbon atoms and at least one carbon-carbon double bond in the ring thereof and no aromaticity, and non-limiting examples thereof include a cyclopentenyl group, a cyclohexenyl group, and a cycloheptenyl group. The term “C<sub>3</sub>-C<sub>10</sub> cycloalkenylene group” as used herein refers to a divalent group having the same structure as the C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group.

[0294] The term “C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group” as used herein refers to a monovalent monocyclic group that has at least one heteroatom selected from N, O, P, Si, and S as a ring-forming atom, 1 to 10 carbon atoms, and at least one carbon-carbon double bond in its ring. Non-limiting examples of the C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group are a 2,3-dihydrofuranlyl group, and a 2,3-dihydrothiophenyl group. The term “C<sub>1</sub>-C<sub>10</sub> heterocycloalkenylene group” as used herein refers to a divalent group having the same structure as the C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group.

[0295] The term “C<sub>6</sub>-C<sub>60</sub> aryl group” as used herein refers to a monovalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms, and the term “C<sub>6</sub>-C<sub>60</sub> arylenylene group” as used herein refers to a divalent group having a carbocyclic aromatic system having 6 to 60 carbon atoms. Non-limiting examples of the C<sub>6</sub>-C<sub>60</sub> aryl group include a phenyl group, a naphthyl group, an anthracenyl group, a phenanthrenyl group, a pyrenyl group, and a chrysenyl group. When the C<sub>6</sub>-C<sub>60</sub> aryl group and the C<sub>6</sub>-C<sub>60</sub> arylenylene group each include two or more rings, the rings may be fused to each other.

[0296] The term “C<sub>7</sub>-C<sub>60</sub> alkylaryl group” as used herein refers to a C<sub>6</sub>-C<sub>60</sub> aryl group substituted with at least one C<sub>1</sub>-C<sub>60</sub> alkyl group.

[0297] The term “C<sub>1</sub>-C<sub>60</sub> heteroaryl group,” as used herein, refers to a monovalent group having a cyclic aromatic system that has at least one heteroatom selected from N, O, P, Si, and S as a ring-forming atom, in addition to 1 to 60 carbon atoms. The term “C<sub>1</sub>-C<sub>60</sub> heteroarylene group” as used herein refers to a divalent group having a cyclic aromatic system that has at least one heteroatom selected from N, O, P, Si, and S as a ring-forming atom, in addition to 1 to 60 carbon atoms. Non-limiting examples of the C<sub>1</sub>-C<sub>60</sub> heteroaryl group include a pyridinyl group, a pyrimidinyl group, a pyrazinyl group, a pyridazinyl group, a triazinyl group, a quinolinyl group, and an isoquinolinyl group. When the C<sub>1</sub>-C<sub>60</sub> heteroaryl group and the C<sub>1</sub>-C<sub>60</sub> heteroarylene group each include two or more rings, the rings may be fused to each other.

[0298] The term “C<sub>2</sub>-C<sub>60</sub> alkylheteroaryl group” as used herein refers to a C<sub>1</sub>-C<sub>60</sub> heteroaryl group substituted with at least one C<sub>1</sub>-C<sub>60</sub> alkyl group.

[0299] The term “C<sub>6</sub>-C<sub>60</sub> aryloxy group” as used herein indicates —OA<sub>102</sub> (wherein A<sub>102</sub> is the C<sub>6</sub>-C<sub>60</sub> aryl group),

and the term C<sub>6</sub>-C<sub>60</sub> arylthio group used herein indicates —SA<sub>103</sub> (wherein A<sub>103</sub> is the C<sub>6</sub>-C<sub>60</sub> aryl group), and the term “C<sub>7</sub>-C<sub>60</sub> arylalkyl group” as used herein indicates —A<sub>104</sub>A<sub>105</sub> (wherein A<sub>105</sub> is the C<sub>6</sub>-C<sub>59</sub> aryl group and A<sub>104</sub> is the C<sub>1</sub>-C<sub>53</sub> alkylene group).

**[0300]** The term “C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group” as used herein refers to —OA<sub>106</sub> (wherein A<sub>106</sub> is the C<sub>2</sub>-C<sub>60</sub> heteroaryl group), the term “C<sub>1</sub>-C<sub>60</sub> heteroarylthio group” as used herein indicates —SA<sub>107</sub> (wherein A<sub>107</sub> is the C<sub>1</sub>-C<sub>60</sub> heteroaryl group), and the term “C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group” as used herein refers to —A<sub>108</sub>A<sub>109</sub> (A<sub>109</sub> is a C<sub>1</sub>-C<sub>59</sub> heteroaryl group, and A<sub>108</sub> is a C<sub>1</sub>-C<sub>59</sub> alkylene group).

**[0301]** The term “monovalent non-aromatic condensed polycyclic group” as used herein refers to a monovalent group (for example, having 8 to 60 carbon atoms) having two or more rings condensed to each other, only carbon atoms as ring-forming atoms, and no aromaticity in its entire molecular structure. Non-limiting examples of the monovalent non-aromatic condensed polycyclic group include a fluorenyl group. The term “divalent non-aromatic condensed polycyclic group” as used herein refers to a divalent group having the same structure as the monovalent non-aromatic condensed polycyclic group.

**[0302]** The term “monovalent non-aromatic condensed heteropolycyclic group” as used herein refers to a monovalent group (for example, having 2 to 60 carbon atoms) having two or more rings condensed to each other, a heteroatom selected from N, O, P, Si, and S, other than carbon atoms, as a ring-forming atom, and no aromaticity in its entire molecular structure. Non-limiting examples of the monovalent non-aromatic condensed heteropolycyclic group include a carbazolyl group. The term “divalent non-aromatic condensed heteropolycyclic group” as used herein refers to a divalent group having the same structure as the monovalent non-aromatic condensed heteropolycyclic group.

**[0303]** The term “C<sub>5</sub>-C<sub>30</sub> carbocyclic group” as used herein refers to a saturated or unsaturated cyclic group having, as a ring-forming atom, 5 to 30 carbon atoms only. The C<sub>5</sub>-C<sub>30</sub> carbocyclic group may be a monocyclic group or a polycyclic group.

**[0304]** The term “C<sub>1</sub>-C<sub>30</sub> heterocyclic group” as used herein refers to a saturated or unsaturated cyclic group having, as a ring-forming atom, at least one heteroatom selected from N, O, Si, P, and S other than 1 to 30 carbon atoms. The C<sub>1</sub>-C<sub>30</sub> heterocyclic group may be a monocyclic group or a polycyclic group.

**[0305]** A substituent(s) of the substituted C<sub>5</sub>-C<sub>30</sub> carbocyclic group, the substituted C<sub>2</sub>-C<sub>30</sub> heterocyclic group, the substituted C<sub>1</sub>-C<sub>60</sub> alkyl group, the substituted C<sub>2</sub>-C<sub>60</sub> alkenyl group, the substituted C<sub>2</sub>-C<sub>60</sub> alkynyl group, the substituted C<sub>1</sub>-C<sub>60</sub> alkoxy group, the substituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, the substituted C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, the substituted C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, the substituted C<sub>1</sub>-C<sub>60</sub> heterocycloalkenyl group, the substituted C<sub>6</sub>-C<sub>60</sub> aryl group, the substituted C<sub>6</sub>-C<sub>60</sub> aryloxy group, the substituted C<sub>6</sub>-C<sub>60</sub> arylthio group, the substituted C<sub>7</sub>-C<sub>60</sub> arylalkyl group, the substituted C<sub>1</sub>-C<sub>60</sub> heteroaryl group, the substituted C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group, the substituted C<sub>1</sub>-C<sub>60</sub> heteroarylthio group, the substituted C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group may be:

**[0306]** deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, or a C<sub>1</sub>-C<sub>60</sub> alkoxy group;

**[0307]** a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, or a C<sub>1</sub>-C<sub>60</sub> alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>7</sub>-C<sub>60</sub> arylalkyl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group, a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group, a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>11</sub>)(Q<sub>12</sub>), —Si(Q<sub>13</sub>)(Q<sub>14</sub>)(Q<sub>15</sub>), —Ge(Q<sub>13</sub>)(Q<sub>14</sub>)(Q<sub>15</sub>), —B(Q<sub>16</sub>)(Q<sub>17</sub>), —P(=O)(Q<sub>18</sub>)(Q<sub>19</sub>), —P(Q<sub>18</sub>)(Q<sub>19</sub>), or any combination thereof;

**[0308]** a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>7</sub>-C<sub>60</sub> arylalkyl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group, a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group, a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, or a monovalent non-aromatic condensed heteropolycyclic group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, a C<sub>1</sub>-C<sub>60</sub> alkoxy group, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>7</sub>-C<sub>60</sub> arylalkyl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group, a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group, a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>21</sub>)(Q<sub>22</sub>), —Si(Q<sub>23</sub>)(Q<sub>24</sub>)(Q<sub>25</sub>), —Ge(Q<sub>23</sub>)(Q<sub>24</sub>)(Q<sub>25</sub>), —B(Q<sub>26</sub>)(Q<sub>27</sub>), —P(=O)(Q<sub>28</sub>)(Q<sub>29</sub>), —P(Q<sub>28</sub>)(Q<sub>29</sub>), or any combination thereof;

**[0309]** —N(Q<sub>31</sub>)(Q<sub>32</sub>), —Si(Q<sub>33</sub>)(Q<sub>34</sub>)(Q<sub>35</sub>), —Ge(Q<sub>33</sub>)(Q<sub>34</sub>)(Q<sub>35</sub>), —B(Q<sub>36</sub>)(Q<sub>37</sub>), —P(=O)(Q<sub>38</sub>)(Q<sub>39</sub>), —P(Q<sub>38</sub>)(Q<sub>39</sub>), or any combination thereof; or

**[0310]** any combination thereof.

**[0311]** In the present specification, Q<sub>1</sub> to Q<sub>9</sub>, Q<sub>11</sub> to Q<sub>19</sub>, Q<sub>21</sub> to Q<sub>29</sub>, and Q<sub>31</sub> to Q<sub>39</sub> may each independently be hydrogen; deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; an amidino group; a hydrazino group; a hydrazono group; a carboxylic acid



group or a salt thereof; a sulfonic acid group or a salt thereof; a phosphoric acid group or a salt thereof; a C<sub>1</sub>-C<sub>60</sub> alkyl group unsubstituted or substituted with deuterium, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, or any combination thereof; a C<sub>2</sub>-C<sub>60</sub> alkenyl group; a C<sub>2</sub>-C<sub>60</sub> alkynyl group; a C<sub>1</sub>-C<sub>60</sub> alkoxy group; a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group; a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group; a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group; a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group; a C<sub>6</sub>-C<sub>60</sub> aryl group unsubstituted or substituted with deuterium, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, or any combination thereof; a C<sub>6</sub>-C<sub>60</sub> aryloxy group; a C<sub>6</sub>-C<sub>60</sub> arylthio group; a C<sub>7</sub>-C<sub>60</sub> arylalkyl group; a C<sub>1</sub>-C<sub>60</sub> heteroaryl group; a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group; a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group; a C<sub>7</sub>-C<sub>60</sub> arylalkyl group; a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group; a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group, a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group, a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group; or a monovalent non-aromatic condensed heteropolycyclic group.

[0312] Hereinafter, a compound and an organic light-emitting device according to embodiments are described in detail with reference to Synthesis Example and Examples. However, the organic light-emitting device is not limited thereto. The wording "B was used instead of A" used in describing Synthesis Examples means that an amount of B used was identical to an amount of A used, in terms of a molar equivalent.

## EXAMPLES

### Synthesis Example 1 (Compound 2)

[0313]



### 1) Synthesis of Intermediate L2

[0314] 1-bromo-isoquinoline (6.58 grams (g), 31.64 millimoles, (mmol)), phenol (3.28 g, 34.80 mmol),  $\text{CuI}$  (0.603 g, 3.06 mmol) and  $\text{Cs}_2\text{CO}_3$  (20.62 g, 63.28 mmol), and pyridine-2-carboxylic acid (0.78 g, 6.33 mmol) were mixed with 160 milliliters (mL) of 1,4-dioxane, and the mixed solution was stirred under reflux for 18 hours. Then, the reaction temperature was lowered to room temperature, a solid produced therein was separated by filtration. A solvent was removed from a filtrate obtained therefrom under reduced pressure, and the resulting residue was extracted by using methylene chloride (MC) to obtain the organic layer. Anhydrous magnesium sulfate ( $\text{MgSO}_4$ ) was added to the organic layer to remove moisture, and the resulting solution was filtered. A solvent was removed from the filtrate obtained therefrom under reduced pressure, and the resulting residue was purified by using column chromatography under conditions of EA (ethyl acetate):Hexane=1:10, thereby obtaining 6.46 g (92%) of Intermediate L2.

[0315] MALDI-TOFMS (m/z):  $\text{C}_{15}\text{H}_{11}\text{NO}$  ( $\text{M}^+$ ) 222.

### 2) Synthesis of Intermediate L2-Dimer

[0316] Intermediate L2 (6.33 g, 28.62 mmol) and iridium chloride (4.49 g, 12.72 mmol) were mixed with 60 mL of ethoxyethanol and 20 mL of distilled water, and the mixed solution was stirred under reflux for 24 hours. Then, the reaction temperature was lowered to room temperature, a solid produced therein was separated by filtration, and the resulting filtrate was thoroughly washed using water/methanol/hexane in the stated order. The solid obtained was then dried in a vacuum oven, thereby obtaining Intermediate L2-dimer (3.69 g, 43%).


### 3) Synthesis of Compound 2

[0317] Intermediate L2-dimer (3.28 g, 2.45 mmol), 2,2,6,6-tetramethylheptane-3,5-dione (4.52 g, 24.5 mmol), and  $\text{Na}_2\text{CO}_3$  (2.59 g, 24.5 mmol) were mixed with 50 mL of ethoxyethanol, and the mixed solution was heated at a temperature of 90° C. for 18 hours while being stirred. The mixture obtained was filtered, and the resulting solid was thoroughly washed using ethanol, and purified by using column chromatography under conditions of dichloromethane:n-hexane=1:1 (v/v), thereby obtaining Compound 2 (1.40 g, 35%). Compound 2 was identified by Mass Spectrum and HPLC.


[0318] HRMS(MALDI) calcd for  $\text{C}_{41}\text{H}_{39}\text{IrN}_2\text{O}_4$ : m/Z 816.2539, Found: 816.2540.

## Synthesis Example 2 (Compound 3)

[0319]



-continued




[0320] Compound 3 (1.6 g, 39%) was obtained in the same manner as in the synthesis of Compound 2 of Synthesis Example 1, except that 3,7-diethylnonane-4,6-dione (5.20 g, 24.5 mmol) was used instead of 2,2,6,6-tetramethylheptane-3,5-dione. Compound 3 was identified by Mass Spectrum and HPLC.

[0321] HRMS(MALDI) calcd for  $\text{C}_{43}\text{H}_{43}\text{IrN}_2\text{O}_4$ :  $m/z$  844.2852, Found: 844.2851.

## Synthesis Example 3 (Compound 32)

[0322]



## 1) Synthesis of Intermediate L32

[0323] Intermediate L32 (6.4 g, 91%) was obtained in the same manner as in the synthesis of Intermediate L2 of Synthesis Example 1, except that 3-bromoisoquinoline (5.20 g, 24.5 mmol) was formed instead of 1-bromo-isoquinoline.

[0324] MALDI-TOFMS ( $m/z$ ):  $\text{C}_{15}\text{H}_{11}\text{NO}$  ( $M^+$ ) 222.

## 2) Synthesis of Intermediate L32-Dimer

[0325] Intermediate L32-dimer (4.5 g, 53%) was obtained in the same manner as in the synthesis of Intermediate L2-dimer of Synthesis Example 1, except that Intermediate L32 (5.20 g, 24.5 mmol) was used instead of Intermediate L2.




## 3) Synthesis of Compound 32

[0326] Compound 32 (1.3 g, 46%) was obtained in the same manner as in the synthesis of Compound 2 of Synthesis Example 1, except that Intermediate L32-dimer (2.29 g, 1.72 mmol) was used instead of Intermediate L2-dimer. Compound 32 was identified by Mass Spectrum and HPLC.

[0327] HRMS(MALDI) calcd for  $C_{41}H_{39}IrN_2O_4$ :  $m/z$  816.2539, Found: 816.2540.

Synthesis Example 4 (Compound 33)

[0328]






[0329] Compound 33 (1.1 g, 39%) was obtained in the same manner as in the synthesis of Compound 32 of

Synthesis Example 3, except that 3,7-diethylnonane-4,6-dione (3.52 g, 16.6 mmol) was used instead of 2,2,6,6-tetramethylheptane-3,5-dione. Compound 33 was identified by Mass Spectrum and HPLC.




[0330] HRMS(MALDI) calcd for  $C_{43}H_{43}IrN_2O_4$ :  $m/z$  844.2852, Found: 844.2851.

Synthesis Example 5 (Compound 47)

[0331]



L47-dimer



### 1) Synthesis of Intermediate L47

**[0332]** Intermediate L47 (3.8 g, 95%) was obtained in the same manner as in the synthesis of Intermediate L2 of Synthesis Example 1, except that 3-bromo-6-phenylisoquinoline (3.82 g, 13.5 mmol) was used instead of 1-bromoisoquinoline.

**[0333]** MALDI-TOFMS (m/z):  $C_{21}H_{15}NO$  ( $M^+$ ) 298.

### 2) Synthesis of Intermediate L47-Dimer

**[0334]** Intermediate L47-dimer (2.2 g, 47%) was obtained in the same manner as in the synthesis of Intermediate L2-dimer of Synthesis Example 1, except that Intermediate L47 (3.8 g, 12.7 mmol) was used instead of Intermediate L2.



### 3) Synthesis of Compound 47

**[0335]** Compound 47 (1.3 g, 46%) was obtained in the same manner as in the synthesis of Compound 2 of Synthesis Example 1, except that Intermediate L47-dimer (2.2 g, 1.72 mmol) was used instead of Intermediate L2-dimer and 3,3,7,7-tetramethylnonane-4,6-dione was used instead of 2,2,6,6-tetramethylheptane-3,5-dione. Compound 47 was identified by Mass Spectrum and HPLC.

**[0336]** HRMS(MALDI) calcd for  $C_{55}H_{51}IrN_2O_4$ : m/z 996.3478, Found: 996.3477.

### Synthesis Example 6 (Compound 69)

**[0337]**



### 1) Synthesis of Intermediate L69

**[0338]** Intermediate L69 (3.2 g, 91%) was obtained in the same manner as in the synthesis of Intermediate L47 of Synthesis Example 5, except that 3,5-dimethylphenol (1.45 g, 11.83 mmol) was used instead of phenol.

**[0339]** MALDI-TOFMS (m/z):  $C_{23}H_{19}NO$  ( $M^+$ ) 326.

## 2) Synthesis of Intermediate L69-Dimer

[0340] Intermediate L69-dimer (1.9 g, 50%) was obtained in the same manner as in the synthesis of Intermediate L47-dimer of Synthesis Example 5, except that Intermediate L69 (3.2 g, 9.76 mmol) was used instead of Intermediate L47.



## 3) Synthesis of Compound 69

[0341] Compound 69 (0.98 g, 43%) was obtained in the same manner as in the synthesis of Compound 47 of Synthesis Example 5, except that Intermediate L69-dimer (1.9 g, 1.09 mmol) was used instead of Intermediate L47-dimer. Compound 69 was identified by Mass Spectrum and HPLC.

[0342] HRMS(MALDI) calcd for  $C_{59}H_{59}IrN_2O_4$ :  $m/z$  1052.4104, Found: 1052.4102.

## Synthesis Example 7 (Compound 239)

## [0343]



## 1) Synthesis of Intermediate L239

[0344] Intermediate L239 (4.4 g, 84%) was obtained in the same manner as in the synthesis of Intermediate L2 of Synthesis Example 1, except that 4-bromobenzo[f]isoquinoline (5.0 g, 19.35 mmol) was used instead of 1-bromoisoquinoline.

## 2) Synthesis of Intermediate L239-Dimer

[0345] Intermediate L239-dimer (1.8 g, 45%) was obtained in the same manner as in the synthesis of Intermediate L2-dimer of Synthesis Example 1, except that Intermediate L239 (3.2 g, 11.71 mmol) was used instead of Intermediate L2.

## 3) Synthesis of Compound 239

[0346] Compound 239 (0.54 g, 27%) was obtained in the same manner as in the synthesis of Compound 2 of Synthesis Example 1, except that Intermediate L239-dimer (1.6 g, 1.06 mmol) was used instead of Intermediate L2-dimer. Compound 239 was identified by Mass Spectrum and HPLC.

[0347] HRMS(MALDI) calcd for  $C_{51}H_{47}IrN_2O_4$ :  $m/z$  944.3165, Found: 944.3161.

## Example 1


[0348] A glass substrate, on which ITO was deposited to as an anode, was cut to a size of 50 mm×50 mm×0.5 mm, sonicated with isopropyl alcohol and pure water each for 5 minutes, and then cleaned by exposure to ultraviolet rays and ozone for 30 minutes. Then, the glass substrate was provided to a vacuum deposition apparatus.

[0349] 2-TNATA was vacuum-deposited on the anode to form a hole injection layer having a thickness of 600 Å, and 4,4'-bis[N-(1-naphthyl)-N-phenylamino]biphenyl (NPB) was vacuum-deposited on the hole injection layer to form a hole transport layer having a thickness of 1,350 Å.


[0350] Then, CBP (host) and Compound 2 (dopant) were co-deposited on the hole transport layer at a weight ratio of 98:2 to form an emission layer having a thickness of 400 Å.

[0351] Afterwards, BCP was vacuum-deposited on the emission layer to form a hole blocking layer having a thickness of 50 Å,  $Alq_3$  was vacuum-deposited on the hole blocking layer to form an electron transport layer having a thickness of 350 Å, LiF was vacuum-deposited on the


electron transport layer to form an electron injection layer having a thickness of 10 Å, and Al was deposited on the electron injection layer to form a cathode, thereby completing the manufacture of an organic light-emitting device:




2-TNATA



NPB



CBP



BCP

Examples 2 to 6 and Comparative Examples A, E, and G

[0352] Organic light-emitting devices were manufactured in the same manner as in Example 1, except that Compounds shown in Table 2 were each used instead of Compound 2 as a dopant in forming an emission layer.

Evaluation Example 1: Evaluation of Characteristics of Organic Light-Emitting Device

[0353] The driving voltage, maximum value of external quantum efficiency (Max EQE), roll-off ratio, half-width, and maximum emission wavelength of a main peak in an EL spectrum, and lifespan (LT<sub>97</sub>) of the organic light-emitting devices manufactured according to Examples 1 to 6 and Comparative Examples A, E, and G were evaluated, and results thereof are shown in Table 2. A current-voltage meter (Keithley 2400) and a luminance meter (Minolta Cs-1000 Å) were used as evaluation devices, and the lifespan (LT<sub>97</sub>) (at 3,500 nit) indicates an amount of time that lapsed when luminance was 97% of initial luminance (100%). The roll-off ratio was calculated by using Equation 20:

$$\text{Roll-off ratio} = \{1 - (\text{efficiency at 3,500 nit} / \text{maximum emission efficiency})\} \times 100\% \quad \text{Equation 20}$$

TABLE 2

	Dopant in emission layer	Driving voltage (V)	Max EQE (%)	Roll-Off ratio (%)	LT <sub>97</sub> (hr) (at 3,500 nit)
Example 1	2	4.7	23.2	10	205
Example 2	69	3.2	31.9	3	557
Example 3	33	4.5	27.8	8	745
Example 4	32	4.3	27.9	7	472
Example 5	47	3.6	29.3	10	580
Example 6	239	4.0	30.2	5	480
Comparative Example A	A	8.8	5.5	39	0.2
Comparative Example E	E	6.4	16.4	25	52
Comparative Example G	G	5.8	22.3	13	175




TABLE 2-continued









Dopant in emission layer	Driving voltage (V)	Max EQE (%)	Roll-Off ratio (%)	LT <sub>97</sub> (hr) (at 3,500 nit)
				
69				
				
33				
				
32				
				
47				

TABLE 2-continued

Dopant in emission layer	Driving voltage (V)	Max EQE (%)	Roll-Off ratio (%)	LT <sub>97</sub> (hr) (at 3,500 nit)
				
239				
				
A				
				
E				
				
G				

[0354] From Table 2, it was confirmed that the organic light-emitting devices of Examples 1 to 6 had improved driving voltage, improved external quantum efficiency, improved roll-off ratio, and improved lifespan characteristics, as compared with those of the organic light-emitting devices of Comparative Examples A, E, and G.

[0355] According to the one or more embodiments, the organometallic compound has improved electric characteristics. In an exemplary embodiment, an organic light-emitting device including the organometallic compound may have improved driving voltage, improved external quantum efficiency, improved roll-off ratio, and improved lifespan characteristics. In addition, the organometallic compound may have improved phosphorescence characteristics, and in


this regard, a diagnostic composition including the organo-metallic compound may have high diagnostic efficiency.

[0356] It should be understood that embodiments described herein should be considered in a descriptive sense only and not for purposes of limitation. Descriptions of features or aspects within each embodiment should typically be considered as available for other similar features or aspects in other embodiments.

[0357] While one or more embodiments have been described with reference to the FIGURES, it will be understood by those of ordinary skill in the art that various changes in form and details may be made therein without departing from the spirit and scope of the present disclosure as defined by the following claims.

What is claimed is:

1. An organometallic compound represented by Formula 1:



wherein, in Formula 1,

M is iridium (Ir), osmium (Os), titanium (Ti), hafnium (Hf), europium (Eu), rhodium (Rh), or ruthenium (Ru),


$L_1$  is a ligand represented by Formula 2,

$n1$  is 1, 2, or 3, and when  $n1$  is 2 or more, two or more groups  $L_1$  are identical to or different from each other,

$L_2$  is a monodentate ligand, a bidentate ligand, a tridentate ligand, or a tetradentate ligand,

$n2$  is 0, 1, 2, 3, or 4, and when  $n2$  is 2 or more, two or more groups  $L_2$  are identical to or different from each other, and

$L_1$  and  $L_2$  are different from each other,



Formula 2

wherein, in Formula 2,

$X_1$  and  $X_{21}$  are each independently C or N,

ring  $CY_{11}$ , ring  $CY_{12}$ , and ring  $CY_{21}$  are each independently a  $C_5$ - $C_{30}$  carbocyclic group or a  $C_1$ - $C_{30}$  heterocyclic group, wherein ring  $CY_{11}$  and ring  $CY_{12}$  are condensed with each other,

$T_1$  is  $^*N(R_2)-^*$ ,  $^*B(R_2)-^*$ ,  $^*P(R_2)-^*$ ,  $^*C(R_2)(R_3)-^*$ ,  $^*Si(R_2)(R_3)-^*$ ,  $^*Ge(R_2)(R_3)-^*$ ,  $^*S-^*$ ,  $^*Se-^*$ ,  $^*O-^*$ ,  $^*C(=O)-^*$ ,  $^*S(=O)-^*$ ,  $^*S(=O)_2-^*$ ,  $^*C(R_2)=^*$ ,  $^*C(R_2)-^*$ ,  $^*C(R_2)=C(R_3)-^*$ ,  $^*C(=S)-^*$ , or  $^*C\equiv C-^*$ , wherein  $^*$  and  $^*$  each indicate a binding site to a neighboring atom,

$R_1$  to  $R_3$  and  $R_{21}$  are each independently hydrogen, deuterium,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-I$ ,  $-SF_5$ , a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group,

a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a substituted or unsubstituted  $C_1$ - $C_{60}$  alkyl group, a substituted or unsubstituted  $C_2$ - $C_{60}$  alkenyl group, a substituted or unsubstituted  $C_2$ - $C_{60}$  alkynyl group, a substituted or unsubstituted  $C_1$ - $C_{60}$  alkoxy group, a substituted or unsubstituted  $C_3$ - $C_{10}$  cycloalkyl group, a substituted or unsubstituted  $C_1$ - $C_{60}$  heterocycloalkyl group, a substituted or unsubstituted  $C_3$ - $C_{10}$  cycloalkenyl group, a substituted or unsubstituted  $C_1$ - $C_{10}$  heterocycloalkenyl group, a substituted or unsubstituted  $C_6$ - $C_{60}$  aryl group, a substituted or unsubstituted  $C_6$ - $C_{60}$  aryloxy group, a substituted or unsubstituted  $C_6$ - $C_{60}$  arylthio group, a substituted or unsubstituted  $C_7$ - $C_{60}$  arylalkyl group, a substituted or unsubstituted  $C_1$ - $C_{60}$  heteroaryl group, a substituted or unsubstituted  $C_1$ - $C_{60}$  heteroaryloxy group, a substituted or unsubstituted  $C_1$ - $C_{60}$  heteroarylthio group, a substituted or unsubstituted  $C_2$ - $C_{60}$  heteroarylalkyl group, a substituted or unsubstituted monovalent non-aromatic condensed polycyclic group, a substituted or unsubstituted monovalent non-aromatic condensed heteropolycyclic group,  $-N(Q_1)(Q_2)$ ,  $-Si(Q_3)(Q_4)(Q_5)$ ,  $-Ge(Q_3)(Q_4)(Q_5)$ ,  $-B(Q_6)(Q_7)$ ,  $-P(=O)(Q_8)(Q_9)$ , or  $-P(Q_8)(Q_9)$ ,

$a1$  and  $a21$  are each independently an integer from 0 to 20, two or more of a plurality of groups  $R_1$  are optionally linked to form a  $C_5$ - $C_{30}$  carbocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$  or a  $C_1$ - $C_{30}$  heterocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$ ,

two or more of a plurality of groups  $R_{21}$  are optionally linked to form a  $C_5$ - $C_{30}$  carbocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$  or a  $C_1$ - $C_{30}$  heterocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$ ,

two or more of  $R_1$  to  $R_3$  and  $R_{21}$  are optionally linked to form a  $C_5$ - $C_{30}$  carbocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$  or a  $C_1$ - $C_{30}$  heterocyclic group that is unsubstituted or substituted with at least one  $R_{10a}$ ,

$R_{10a}$  is the same as defined in connection with  $R_{21}$ ,

$^*$  and  $^*$  each indicate a binding site to M in Formula 1, and

a substituent(s) of the substituted  $C_1$ - $C_{60}$  alkyl group, the substituted  $C_2$ - $C_{60}$  alkenyl group, the substituted  $C_2$ - $C_{60}$  alkynyl group, the substituted  $C_1$ - $C_{60}$  alkoxy group, the substituted  $C_3$ - $C_{10}$  cycloalkyl group, the substituted  $C_1$ - $C_{60}$  heterocycloalkyl group, the substituted  $C_3$ - $C_{10}$  cycloalkenyl group, the substituted  $C_1$ - $C_{60}$  heterocycloalkenyl group, the substituted  $C_6$ - $C_{60}$  aryl group, the substituted  $C_6$ - $C_{60}$  aryloxy group, the substituted  $C_6$ - $C_{60}$  arylthio group, the substituted  $C_7$ - $C_{60}$  arylalkyl group, the substituted  $C_1$ - $C_{60}$  heteroaryl group, the substituted  $C_1$ - $C_{60}$  heteroaryloxy group, the substituted  $C_1$ - $C_{60}$  heteroarylthio group, the substituted  $C_2$ - $C_{60}$  heteroarylalkyl group, the substituted monovalent non-aromatic condensed polycyclic group, and the substituted monovalent non-aromatic condensed heteropolycyclic group is each independently:

deuterium,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-I$ ,  $-CD_3$ ,  $-CD_2H$ ,  $-CDH_2$ ,  $-CF_3$ ,  $-CF_2H$ ,  $-CFH_2$ , a hydroxyl group, a cyano group, a nitro group, an amino group, an

amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, or a C<sub>1</sub>-C<sub>60</sub> alkoxy group;

a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, or a C<sub>1</sub>-C<sub>60</sub> alkoxy group, each substituted with deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>7</sub>-C<sub>60</sub> arylalkyl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group, a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group, a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>11</sub>)(Q<sub>12</sub>), —Si(Q<sub>13</sub>)(Q<sub>14</sub>)(Q<sub>15</sub>), —Ge(Q<sub>13</sub>)(Q<sub>14</sub>)(Q<sub>15</sub>), —B(Q<sub>16</sub>)(Q<sub>17</sub>), —P(=O)(Q<sub>18</sub>)(Q<sub>19</sub>), —P(Q<sub>18</sub>)(Q<sub>19</sub>), or any combination thereof;

a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>7</sub>-C<sub>60</sub> arylalkyl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group, a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group, a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, or a monovalent non-aromatic condensed heteropolycyclic group, each unsubstituted or substituted with deuterium, —F, —Cl, —Br, —I, —CD<sub>3</sub>, —CD<sub>2</sub>H, —CDH<sub>2</sub>, —CF<sub>3</sub>, —CF<sub>2</sub>H, —CFH<sub>2</sub>, a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazino group, a hydrazono group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>2</sub>-C<sub>60</sub> alkenyl group, a C<sub>2</sub>-C<sub>60</sub> alkynyl group, a C<sub>1</sub>-C<sub>60</sub> alkoxy group, a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group, a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, a C<sub>6</sub>-C<sub>60</sub> aryloxy group, a C<sub>6</sub>-C<sub>60</sub> arylthio group, a C<sub>7</sub>-C<sub>60</sub> arylalkyl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryl group, a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group, a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group, a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group, a monovalent non-aromatic condensed polycyclic group, a monovalent non-aromatic condensed heteropolycyclic group, —N(Q<sub>21</sub>)(Q<sub>22</sub>), —Si(Q<sub>23</sub>)(Q<sub>24</sub>)(Q<sub>25</sub>), —Ge(Q<sub>23</sub>)(Q<sub>24</sub>)(Q<sub>25</sub>), —B(Q<sub>26</sub>)(Q<sub>27</sub>), —P(=O)(Q<sub>28</sub>)(Q<sub>19</sub>), —P(Q<sub>28</sub>)(Q<sub>29</sub>), or any combination thereof;

—N(Q<sub>31</sub>)(Q<sub>32</sub>), —Si(Q<sub>33</sub>)(Q<sub>34</sub>)(Q<sub>35</sub>), —Ge(Q<sub>33</sub>)(Q<sub>34</sub>)(Q<sub>35</sub>), —B(Q<sub>36</sub>)(Q<sub>37</sub>), —P(=O)(Q<sub>38</sub>)(Q<sub>39</sub>), or —P(Q<sub>38</sub>)(Q<sub>39</sub>); or  
any combination thereof, and  
Q<sub>1</sub> to Q<sub>9</sub>, Q<sub>11</sub> to Q<sub>19</sub>, Q<sub>21</sub> to Q<sub>29</sub>, and Q<sub>31</sub> to Q<sub>39</sub> are each independently hydrogen; deuterium; —F; —Cl; —Br; —I; a hydroxyl group; a cyano group; a nitro group; an amino group; a guanidino group; an amidino group; a guanidino group; a hydrazine group; a hydrazone group; a carboxylic acid group or a salt thereof a

sulfonic acid group or a salt thereof; a phosphoric acid group or a salt thereof; a C<sub>1</sub>-C<sub>60</sub> alkyl group unsubstituted or substituted with deuterium, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, or any combination thereof; a C<sub>2</sub>-C<sub>60</sub> alkenyl group; a C<sub>2</sub>-C<sub>60</sub> alkynyl group; a C<sub>1</sub>-C<sub>60</sub> alkoxy group; a C<sub>3</sub>-C<sub>10</sub> cycloalkyl group; a C<sub>1</sub>-C<sub>10</sub> heterocycloalkyl group; a C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group; a C<sub>1</sub>-C<sub>10</sub> heterocycloalkenyl group; a C<sub>6</sub>-C<sub>60</sub> aryl group unsubstituted or substituted with deuterium, a C<sub>1</sub>-C<sub>60</sub> alkyl group, a C<sub>6</sub>-C<sub>60</sub> aryl group, or any combination thereof; a C<sub>6</sub>-C<sub>60</sub> aryloxy group; a C<sub>6</sub>-C<sub>60</sub> arylthio group; a C<sub>7</sub>-C<sub>60</sub> arylalkyl group; a C<sub>1</sub>-C<sub>60</sub> heteroaryl group; a C<sub>1</sub>-C<sub>60</sub> heteroaryloxy group; a C<sub>1</sub>-C<sub>60</sub> heteroarylthio group; a C<sub>2</sub>-C<sub>60</sub> heteroarylalkyl group; a monovalent non-aromatic condensed polycyclic group; or a monovalent non-aromatic condensed heteropolycyclic group.

- The organometallic compound of claim 1, wherein M is Ir or Os, and the sum of n1 and n2 is 3 or 4.
- The organometallic compound of claim 1, wherein X<sub>1</sub> is N and X<sub>21</sub> is C.
- The organometallic compound of claim 1, wherein ring CY<sub>11</sub>, ring CY<sub>12</sub>, and ring CY<sub>21</sub> are each independently a cyclopentene group, a cyclohexene group, a cycloheptene group, a benzene group, a naphthalene group, an anthracene group, a fluoranthene group, a phenanthrene group, a triphenylene group, a pyrene group, a chrysene group, a 1,2,3,4-tetrahydronaphthalene group, a pyrrole group, a borole group, a phosphole group, a cyclopentadiene group, a silole group, a germole group, a thiophene group, a selenophene group, a furan group, an indole group, a benzoborole group, a benzophosphole group, an indene group, a benzosilole group, a benzogermole group, a benzothiophene group, a benzoselenophene group, a benzofuran group, a carbazole group, a dibenzoborole group, a dibenzophosphole group, a fluorene group, a dibenzosilole group, a dibenzogermole group, a dibenzothiophene group, a dibenzoselenophene group, a dibenzofuran group, a dibenzothiophene 5-oxide group, a 9H-fluorene-9-one group, a dibenzothiophene 5,5-dioxide group, an azaindole group, an azabenzoborole group, an azabenzophosphole group, an azaindene group, an azabenzosilole group, an azabenzogermole group, an azabenzothiophene group, an azabenzoselenophene group, an azabenzofuran group, an azacarbazole group, an azadibenzoborole group, an azadibenzophosphole group, an azafluorene group, an azadibenzosilole group, an azadibenzogermole group, an azadibenzothiophene group, an azadibenzoselenophene group, an azadibenzofuran group, an azadibenzothiophene 5-oxide group, an aza-9H-fluorene-9-one group, an azadibenzothiophene 5,5-dioxide group, a pyridine group, a pyrimidine group, a pyrazine group, a pyridazine group, a triazine group, a quinoline group, an isoquinoline group, a benzoquinoline group, a benzoisoquinoline group, a quinoxaline group, a quinazoline group, a phenanthroline group, a pyrazole group, an imidazole group, a triazole group, an azaborole group, an azaphosphole group, an azacyclopentadiene group, an azasilole group, an azagermole group, an azaselenophene group, an oxazole group, an isooxazole group, a thiazole group, an isothiazole group, an oxadiazole group, a thiadiazole group, a benzopyrazole

group, a benzimidazole group, a benzoxazole group, a benzothiazole group, a benzoxadiazole group, a benzothiadiazole group, a 5,6,7,8-tetrahydroisoquinoline group, or a 5,6,7,8-tetrahydroquinoline group.

5. The organometallic compound of claim 1, wherein  $T_1$  is  $*-O-*$ .

6. The organometallic compound of claim 1, wherein  $R_1$  to  $R_3$  and  $R_{21}$  are each independently:

hydrogen, deuterium,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-I$ , a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof,  $-SF_5$ ,  $C_1-C_{20}$  alkyl group, or a  $C_1-C_{20}$  alkoxy group;

a  $C_1-C_{20}$  alkyl group and a  $C_1-C_{20}$  alkoxy group, each substituted with deuterium,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-I$ ,  $-CD_3$ ,  $-CD_2H$ ,  $-CDH_2$ ,  $-CF_3$ ,  $-CF_2H$ ,  $-CFH_2$ , a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_1-C_{10}$  alkyl group, a  $C_1-C_{20}$  alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantyl group, a norbornyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, a  $(C_1-C_{20}$  alkyl)cyclopentyl group, a  $(C_1-C_{20}$  alkyl)cyclohexyl group, a  $(C_1-C_{20}$  alkyl)cycloheptyl group, a  $(C_1-C_{20}$  alkyl)cyclooctyl group, a  $(C_1-C_{20}$  alkyl)adamantanyl group, a  $(C_1-C_{20}$  alkyl)norbornanyl group, a  $(C_1-C_{20}$  alkyl)norbornenyl group, a  $(C_1-C_{20}$  alkyl)cyclopentenyl group, a  $(C_1-C_{20}$  alkyl)cyclohexenyl group, a  $(C_1-C_{20}$  alkyl)cycloheptenyl group, a  $(C_1-C_{20}$  alkyl)bicyclo[1.1.1]pentyl group, a  $(C_1-C_{20}$  alkyl)bicyclo[2.1.1]hexyl group, a  $(C_1-C_{20}$  alkyl)bicyclo[2.2.1]heptyl group, a  $(C_1-C_{20}$  alkyl)bicyclo[2.2.2]octyl group, a phenyl group, a  $(C_1-C_{20}$  alkyl)phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a pyridinyl group, or any combination thereof;

a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantyl group, a norbornyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, a phenyl group, a  $(C_1-C_{20}$  alkyl)phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranlyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranlyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranlyl group, an azadibenzothiophenyl group, or any combination thereof; or

phenanthrolinyl group, a benzimidazolyl group, a benzofuranlyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranlyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranlyl group, or an azadibenzothiophenyl group, each unsubstituted or substituted with deuterium,  $-F$ ,  $-Cl$ ,  $-Br$ ,  $-I$ ,  $-CD_3$ ,  $-CD_2H$ ,  $-CDH_2$ ,  $-CF_3$ ,  $-CF_2H$ ,  $-CFH_2$ , a hydroxyl group, a cyano group, a nitro group, an amino group, an amidino group, a hydrazine group, a hydrazone group, a carboxylic acid group or a salt thereof, a sulfonic acid group or a salt thereof, a phosphoric acid group or a salt thereof, a  $C_1-C_{20}$  alkyl group, a deuterium-containing  $C_2-C_{20}$  alkyl group, a  $C_1-C_{20}$  alkoxy group, a cyclopentyl group, a cyclohexyl group, a cycloheptyl group, a cyclooctyl group, an adamantyl group, a norbornyl group, a norbornenyl group, a cyclopentenyl group, a cyclohexenyl group, a cycloheptenyl group, a bicyclo[1.1.1]pentyl group, a bicyclo[2.1.1]hexyl group, a bicyclo[2.2.1]heptyl group, a bicyclo[2.2.2]octyl group, a  $(C_1-C_{20}$  alkyl)cyclopentyl group, a  $(C_1-C_{20}$  alkyl)cyclohexyl group, a  $(C_1-C_{20}$  alkyl)cycloheptyl group, a  $(C_1-C_{20}$  alkyl)cyclooctyl group, a  $(C_1-C_{20}$  alkyl)adamantanyl group, a  $(C_1-C_{20}$  alkyl)norbornanyl group, a  $(C_1-C_{20}$  alkyl)norbornenyl group, a  $(C_1-C_{20}$  alkyl)cyclopentenyl group, a  $(C_1-C_{20}$  alkyl)cyclohexenyl group, a  $(C_1-C_{20}$  alkyl)cycloheptenyl group, a  $(C_1-C_{20}$  alkyl)bicyclo[1.1.1]pentyl group, a  $(C_1-C_{20}$  alkyl)bicyclo[2.1.1]hexyl group, a  $(C_1-C_{20}$  alkyl)bicyclo[2.2.1]heptyl group, a  $(C_1-C_{20}$  alkyl)bicyclo[2.2.2]octyl group, a phenyl group, a  $(C_1-C_{20}$  alkyl)phenyl group, a biphenyl group, a terphenyl group, a naphthyl group, a fluorenyl group, a phenanthrenyl group, an anthracenyl group, a fluoranthenyl group, a triphenylenyl group, a pyrenyl group, a chrysenyl group, a pyrrolyl group, a thiophenyl group, a furanyl group, an imidazolyl group, a pyrazolyl group, a thiazolyl group, an isothiazolyl group, an oxazolyl group, an isoxazolyl group, a pyridinyl group, a pyrazinyl group, a pyrimidinyl group, a pyridazinyl group, an isoindolyl group, an indolyl group, an indazolyl group, a purinyl group, a quinolinyl group, an isoquinolinyl group, a benzquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a cinnolinyl group, a carbazolyl group, a phenanthrolinyl group, a benzimidazolyl group, a benzofuranlyl group, a benzothiophenyl group, an isobenzothiazolyl group, a benzoxazolyl group, an isobenzoxazolyl group, a triazolyl group, a tetrazolyl group, an oxadiazolyl group, a triazinyl group, a dibenzofuranlyl group, a dibenzothiophenyl group, a benzocarbazolyl group, a dibenzocarbazolyl group, an imidazopyridinyl group, an imidazopyrimidinyl group, an azacarbazolyl group, an azadibenzofuranlyl group, an azadibenzothiophenyl group, or any combination thereof; or

$-N(Q_1)(Q_2)$ ,  $-Si(Q_3)(Q_4)(Q_5)$ ,  $-Ge(Q_3)(Q_4)(Q_5)$ ,  $-B(Q_6)(Q_7)$ ,  $-P(=O)(Q_8)(Q_9)$ , or  $-P(Q_8)(Q_9)$ , and


$Q_1$  to  $Q_9$  are each independently:

$-CH_3$ ,  $-CD_3$ ,  $-CD_2H$ ,  $-CDH_2$ ,  $-CH_2CH_3$ ,  $-CH_2CD_3$ ,  $-CH_2CD_2H$ ,  $-CH_2CDH_2$ ,  $-CHDCH_3$ ,


—CHDCD<sub>2</sub>H, —CHDCDH<sub>2</sub>, —CHDCD<sub>3</sub>,  
—CD<sub>2</sub>CD<sub>3</sub>, —CD<sub>2</sub>CD<sub>2</sub>H, or —CD<sub>2</sub>CDH<sub>2</sub>; or

an n-propyl group, an iso-propyl group, an n-butyl group, a sec-butyl group, an iso-butyl group, a tert-butyl group, an n-pentyl group, a tert-pentyl group, a neo-pentyl group, an iso-pentyl group, a sec-pentyl group, a 3-pentyl group, a sec-iso-pentyl group, a phenyl group, a biphenyl group or a naphthyl group, each unsubstituted or substituted with deuterium, a C<sub>1</sub>-C<sub>10</sub> alkyl group, a phenyl group, or any combination thereof.


7. The organometallic compound of claim 1, wherein a group represented by




in Formula 2 is a group represented by one of Formulae CY1-1 to CY1-69:




CY1-1




CY1-2



CY1-3




CY1-4




CY1-5


-continued




CY1-6




CY1-7




CY1-8




CY1-9



CY1-10









CY1-11




CY1-12


-continued




CY1-13




CY1-14




CY1-15




CY1-16



CY1-17



CY1-18



-continued

CY1-19

CY1-20







CY1-21

CY1-22

CY1-23


CY1-24

-continued




-continued


CY1-25




CY1-26




CY1-27




CY1-28



CY1-29



CY1-30



CY1-31

CY1-32

CY1-33

CY1-34







CY1-35

CY1-36

CY1-37


CY1-38

-continued




-continued


CY1-39




CY1-40




CY1-41




CY1-42



CY1-43



CY1-44



CY1-45

CY1-46







CY1-47

CY1-48

CY1-49


CY1-50

-continued




-continued


CY1-51




CY1-52




CY1-53




CY1-54



CY1-55



CY1-56



CY1-57

CY1-58

CY1-59






CY1-60

CY1-61

CY1-62


CY1-63

-continued



-continued

CY1-64



CY1-69

CY1-65

wherein, in Formulae CY1-1 to CY1-69,

$X_1$  and  $R_1$  are each the same as defined in claim 1,

$X_{11}$  is O, S, Se, N( $R_{19}$ ), C( $R_{19a}$ )( $R_{19b}$ ), or Si( $R_{19a}$ )( $R_{19b}$ ),

$R_{19}$ ,  $R_{19a}$ ,  $R_{19b}$ ,  $R_{1a}$  and  $R_{1b}$  are each the same as defined in connection with  $R_1$  in claim 1,

$a_{18}$  is an integer from 0 to 8,

$a_{16}$  is an integer from 0 to 6,

$a_{15}$  is an integer from 0 to 5,

$a_{14}$  is an integer from 0 to 4,

CY1-66


$a_{13}$  is an integer from 0 to 3,

\*'' indicates a binding site to  $T_1$  in Formula 2, and

\*' indicates a binding site to M in Formula 1.


8. The organometallic compound of claim 1, wherein a group represented by

CY1-67




in Formula 2 is a group represented by one of Formulae CY21-1 to CY21-25:

CY21-1











CY1-68

CY21-2




-continued




-continued


CY21-3




CY21-4



CY21-5




CY21-6




CY21-8

CY21-9



CY21-10



CY21-11

CY21-12







CY21-13

CY21-14

CY21-15


CY21-16

-continued




-continued


CY21-17



CY21-18



CY21-19




CY21-20

wherein, in Formulae CY21-1 to CY21-25, X<sub>21</sub> and R<sub>21</sub> are each the same as defined in claim 1, X<sub>22</sub> is C(R<sub>22</sub>)(R<sub>23</sub>), N(R<sub>22</sub>), O, S, or Si(R<sub>22</sub>)(R<sub>23</sub>), R<sub>22</sub> to R<sub>29</sub> are each the same as defined in connection with R<sub>21</sub> in claim 1, a<sub>26</sub> is an integer from 0 to 6, a<sub>24</sub> is an integer from 0 to 4, a<sub>23</sub> is an integer from 0 to 3, a<sub>22</sub> is an integer from 0 to 2, \*\* indicates a binding site to T<sub>1</sub> in Formula 2, and \* indicates a binding site to M in Formula 1.

CY21-21

9. The organometallic compound of claim 8, wherein a group represented by



CY21-22


in Formula 2 is a group represented by one of Formulae CY21(1) to CY21(56) and Formula CY21-20 to CY21-25:

CY21-23









CY21-24

CY21-25

CY21(1)




-continued




-continued


CY21(2)




CY21(3)




CY21(4)




CY21(5)




CY21(6)



CY21(7)



CY21(8)



CY21(9)

CY21(10)

CY21(11)

CY21(12)








CY21(13)

CY21(14)

CY21(5)

CY21(16)

-continued



CY21(17)

CY21(18)

CY21(19)








CY21(20)

CY21(21)

CY21(22)

CY21(23)

-continued



CY21(24)

CY21(25)

CY21(26)









CY21(27)

CY21(28)

CY21(29)


CY21(30)

-continued




-continued


CY21(31)




CY21(32)




CY21(33)




CY21(34)




CY21(35)




CY21(36)



CY21(37)



CY21(38)



CY21(39)

CY21(40)

CY21(41)

CY21(42)









CY21(43)

CY21(44)

CY21(45)


CY21(46)

-continued




-continued

CY21(47)



CY21(55)

CY21(48)



CY21(56)

CY21(49)

wherein, in Formulae CY21 (1) to CY21(56),  
 $X_{21}$  and  $R_{21}$  are each the same as defined in claim 1  
 $R_{21a}$  to  $R_{21d}$  are each the same as defined in connection  
 with  $R_{21}$  in claim 1, wherein each of  $R_{21}$  and  $R_{21a}$  to  
 $R_{21d}$  is not hydrogen,

CY21(50)


\*'' indicates a binding site to  $T_1$  in Formula 2, and  
 \*' indicates a binding site to M in Formula 1.

10. The organometallic compound of claim 1, wherein  
 $L_2$  in Formula 1 is a bidentate ligand each linked to M in  
 Formula 1 via O, S, Se, N, C, P, Si, or As.

11. The organometallic compound of claim 1, wherein  
 $L_2$  in Formula 1 is a bidentate ligand represented by  
 Formula 3.

CY21(51)

Formula 3



CY21(52)

wherein, in Formula 3,  $X_{31}$  and  $X_{32}$  are each independ-  
 ently O, S, Se, or N,



CY21(53)


indicates a linking group linking  $X_{31}$  and  $X_{32}$  together,  
 and

\* and \*' each indicate a binding site to M in Formula 1.






12. The organometallic compound of claim 1, wherein  
 $L_2$  in Formula 1 is a group represented by one of Formulae  
 3A to 3F:

CY21(54)

3A



-continued



wherein, in Formulae 3A to 3F,

Y<sub>13</sub> is O, N, N(Z<sub>1</sub>), P(Z<sub>1</sub>)(Z<sub>2</sub>), or As(Z<sub>1</sub>)(Z<sub>2</sub>),

Y<sub>14</sub> is O, N, N(Z<sub>3</sub>), P(Z<sub>3</sub>)(Z<sub>4</sub>), or As(Z<sub>3</sub>)(Z<sub>4</sub>),

T<sub>11</sub> is a single bond, a double bond, \*—C(Z<sub>11</sub>)(Z<sub>12</sub>)—\*, \*—C(Z<sub>11</sub>)=C(Z<sub>12</sub>)—\*, \*—C(Z<sub>11</sub>)—\*,

—C(Z<sub>11</sub>)=\*, \*—C(Z<sub>11</sub>)—C(Z<sub>12</sub>)=C(Z<sub>13</sub>)—\*, \*—C(Z<sub>11</sub>)=C(Z<sub>12</sub>)—C(Z<sub>13</sub>)=\*, \*—N(Z<sub>11</sub>)—\*, or a C<sub>5</sub>-C<sub>30</sub> carbocyclic group unsubstituted or substituted with at least one Z<sub>11</sub>,

a<sub>11</sub> is an integer from 1 to 10, when a<sub>11</sub> is 2 or more, two or more groups T<sub>11</sub> are identical to or different from each other,

Y<sub>11</sub> and Y<sub>12</sub> are each independently C or N,

T<sub>21</sub> is a single bond, a double bond, O, S, C(Z<sub>11</sub>)(Z<sub>12</sub>), Si(Z<sub>11</sub>)(Z<sub>12</sub>), or N(Z<sub>11</sub>)

ring CY<sub>11</sub> and ring CY<sub>12</sub> are each independently a C<sub>5</sub>-C<sub>30</sub> carbocyclic group or a C<sub>1</sub>-C<sub>30</sub> heterocyclic group,

A<sub>1</sub> is P or As,

Z<sub>1</sub> to Z<sub>4</sub> and Z<sub>1</sub> to Z<sub>13</sub> are each the same as defined in connection with R<sub>21</sub> in claim 2,

d<sub>1</sub> and d<sub>2</sub> are each independently an integer from 0 to 10, and

\* and \*' each indicate a binding site to M in Formula 1.

13. The organometallic compound of claim 1, wherein L<sub>2</sub> in Formula 1 is a group represented by one of Formulae 3-1(1) to 3-1(66) and 3-1(301) to 3-1(309):







3B

3C

3D

3E

3F



3-1(1)

3-1(2)


3-1(3)

3-1(4)


3-1(5)

3-1(6)


-continued




3-1(7)




3-1(8)




3-1(9)



3-1(10)




3-1(11)




3-1(12)


-continued




3-1(13)




3-1(14)




3-1(15)



3-1(16)




3-1(17)




3-1(18)

-continued




3-1(19)


-continued




3-1(24)




3-1(20)




3-1(25)




3-1(21)




3-1(26)




3-1(22)



3-1(27)




3-1(23)




3-1(28)


-continued




3-1(29)




3-1(34)




3-1(30)




3-1(35)




3-1(31)




3-1(36)




3-1(32)



3-1(37)




3-1(33)




3-1(38)


-continued




3-1(39)




3-1(44)




3-1(40)




3-1(45)




3-1(41)




3-1(46)




3-1(42)



3-1(47)




3-1(43)




3-1(48)

-continued




3-1(49)


-continued




3-1(53)




3-1(50)




3-1(54)




3-1(51)



3-1(55)




3-1(52)




3-1(56)


-continued




3-1(57)



3-1(58)




3-1(59)




3-1(60)


-continued




3-1(61)



3-1(62)










3-1(63)




3-1(64)

-continued




-continued

3-1(65)




3-1(307)

3-1(301)



3-1(308)

3-1(302)



3-1(309)

wherein in Formulae 31(1) to 31(66) and 31(301) to 31(309),


X<sub>41</sub> is O, S, N(Z<sub>21</sub>), C(Z<sub>21</sub>)(Z<sub>22</sub>), or Si(Z<sub>21</sub>)(Z<sub>22</sub>), Z<sub>1</sub> to Z<sub>4</sub>, Z<sub>1a</sub>, Z<sub>1b</sub>, Z<sub>1c</sub>, Z<sub>1d</sub>, Z<sub>2a</sub>, Z<sub>2b</sub>, Z<sub>2c</sub>, Z<sub>2d</sub>, and Z<sub>11</sub> to Z<sub>14</sub> may each be the same as defined in connection with R<sub>21</sub> in claim 1,

d<sub>14</sub> may be an integer from 0 to 4,  
d<sub>26</sub> may be an integer from 0 to 6,

\* and \*' each indicate a binding site to M in Formula 1.  
**14.** The organometallic compound of claim 1, wherein L<sub>2</sub> in Formula 1 is a group represented by Formula 3-1-1:

3-1(303)

3-1(304)



3-1-1

3-1(305)

wherein, in Formula 3-1-1,  
Z<sub>12</sub> is the same as defined in connection with R<sub>21</sub> in claim 1,


3-1(306)

A<sub>2</sub> and A<sub>5</sub> are each independently hydrogen, deuterium, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> alkyl group, a substituted or unsubstituted C<sub>2</sub>-C<sub>60</sub> alkenyl group, a substituted or unsubstituted C<sub>2</sub>-C<sub>60</sub> alkynyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> alkoxy group, a substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> heterocycloalkyl group, a substituted or unsubstituted C<sub>3</sub>-C<sub>10</sub> cycloalkenyl group, a substituted or unsubstituted C<sub>1</sub>-C<sub>60</sub> heterocycloalkenyl group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> aryl group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> aryloxy group, a substituted or unsubstituted C<sub>6</sub>-C<sub>60</sub> arylthio group, a substituted or unsubstituted C<sub>7</sub>-C<sub>60</sub> arylalkyl group, a substituted or unsubstituted




$C_1$ - $C_{60}$  heteroaryloxy group; a  $C_1$ - $C_{60}$  heteroarylthio group; a  $C_2$ - $C_{60}$  heteroarylalkyl group; a monovalent non-aromatic condensed polycyclic group; or a monovalent non-aromatic condensed heteropolycyclic group.


15. The organometallic compound of claim 1, wherein the organometallic compound is one of Compounds 1 to 366:




1



2




3




4


-continued




5



6




7










8





-continued







-continued




-continued



-continued




-continued




25


-continued




29




26




30




27



31







28







32


-continued




-continued




-continued




-continued




-continued




48



49




50




51


-continued



52




53




54

-continued




55


-continued




58




56



59




57




60

-continued




61


-continued




64




62



65




63




66

-continued




67


-continued




70




68




71



69








72




73

-continued




-continued

74




79

76




80

76




81

77




82

78




83

-continued




84


-continued




89




85




90




86




91




87



92




88




93

-continued




94


-continued




99




95




100




96




101




97



102




98










103





-continued







-continued



-continued











-continued







-continued





-continued




-continued



-continued




-continued




136


-continued




140




137




141




138



142




139




143


-continued




144



145




146




147


-continued



148











149




150

-continued


-continued




-continued




160




161




162




-continued




164



165




-continued




166

-continued




170


167




171




168




172



169











173




-continued

-continued




-continued




182


-continued




186




183




187




184



188







185




189

-continued




-continued

190




194

191




195

192




196

193




197

-continued




198


-continued




202




199




203




200



204




201




205

-continued




206


-continued




210




207




211




208



212




209




213

-continued




214


-continued




218




215




219



216






217







220

-continued



-continued




224

225






226

227





-continued



-continued




-continued




-continued

234




238

235




239

236






240

237







241


-continued




-continued




-continued




-continued




250




253







251







254




-continued




-continued



-continued





-continued





267



268



269











270




-continued

-continued







-continued




287



288




289




290


-continued




291



292







293







294


-continued








-continued



-continued




-continued




-continued


309




310



311




312




-continued


313



314









315




-continued

-continued




-continued




322

-continued




325

323





326




324

327




-continued




328


-continued




331




329



332




330









333




-continued



-continued




-continued




-continued

341




344

342




345

343




346

347




-continued




348


-continued




351




349




352



350




353







354




-continued




-continued



-continued



-continued



**16.** An organic light-emitting device comprising:  
 a first electrode;  
 a second electrode; and  
 an organic layer disposed between the first electrode and the second electrode and comprising an emission layer, wherein the organic layer comprises at least one organometallic compound of claim 1.

**17.** The organic light-emitting device of claim 16, wherein the first electrode is an anode, the second electrode is a cathode, the organic layer further comprises a hole transport region disposed between the first electrode and the emission layer and an electron transport region disposed between the emission layer and the second electrode, the hole transport region comprises a hole injection layer, a hole transport layer, an electron blocking layer, a buffer layer, or any combination thereof, and the electron transport region comprises a hole blocking layer, an electron transport layer, an electron injection layer, or any combination thereof.

**18.** The organic light-emitting device of claim 16, wherein the emission layer comprises the organometallic compound.

**19.** The organic light-emitting device of claim 18, wherein the emission layer further comprises a host, and an amount of the host in the emission layer is larger than an amount of the organometallic compound in the emission layer.

**20.** A diagnostic composition comprising at least one organometallic compound of claim 1.

\* \* \* \* \*

专利名称(译)	有机金属化合物，包括该有机金属化合物的有机发光器件以及包括该有机金属化合物的诊断组合物		
公开(公告)号	<a href="#">US20200083464A1</a>	公开(公告)日	2020-03-12
申请号	US16/555257	申请日	2019-08-29
[标]申请(专利权)人(译)	三星电子株式会社		
申请(专利权)人(译)	SAMSUNG ELECTRONICS CO. , LTD.		
当前申请(专利权)人(译)	SAMSUNG ELECTRONICS CO. , LTD.		
[标]发明人	CHOI HYEONHO HWANG KYUYOUNG KWAK SEUNGYEON NAM YOUNGMIN LEE KUM HEE JEON ARAM CHOI WHAIL KIM KYUNGDOC YOO JIHO CHOI YOUNSUK		
发明人	CHOI, HYEONHO HWANG, KYUYOUNG KWAK, SEUNGYEON NAM, YOUNGMIN LEE, KUM HEE JEON, ARAM CHOI, WHAIL KIM, KYUNGDOC YOO, JIHO CHOI, YOUNSUK		
IPC分类号	H01L51/00 C07F15/00 C09K11/06		
CPC分类号	H01L51/5056 H01L51/5016 H01L51/0085 H01L51/5096 H01L51/5088 H01L51/5092 H01L51/5072 C07F15/0033 C09K2211/185 C09K11/06 C09K2211/1029 H01L51/5024		
优先权	1020180104040 2018-08-31 KR 1020190105899 2019-08-28 KR		
外部链接	<a href="#">Espacenet</a> <a href="#">USPTO</a>		

#### 摘要(译)

式1表示的有机金属化合物： $M(L_1)_{n1}(L_2)_{n2}$  公式1 其中，在式1中，M为L<sub>1</sub>，L<sub>2</sub>，n<sub>1</sub>和n<sub>2</sub>均与本规范的详细说明中定义的相同。

